

BIO KEY INTERNATIONAL INC

Form 10-Q

November 13, 2009

[Table of Contents](#)

U.S. SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

QUARTERLY REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT
OF 1934

For the quarterly period ended September 30, 2009

or

TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE EXCHANGE ACT

For the Transition Period from to

Commission file number 1-13463

BIO-KEY INTERNATIONAL, INC.

(Exact Name of Registrant as Specified in Its Charter)

DELAWARE

41-1741861

Edgar Filing: BIO KEY INTERNATIONAL INC - Form 10-Q

(State or Other Jurisdiction of
Incorporation of Organization)

(IRS Employer
Identification Number)

3349 HIGHWAY 138, BUILDING D, SUITE B, WALL, NJ 07719

(Address of Principal Executive Offices)

(732) 359-1100

(Issuer's Telephone Number)

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act.

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller Reporting Company

Indicate by check mark whether the registrant is a shell company (as defined by rule 12b-2 of the Exchange Act) Yes No

Number of shares of Common Stock, \$.0001 par value per share, outstanding as of November 13, 2009 were 77,244,711.

Table of Contents

BIO-KEY INTERNATIONAL, INC.

INDEX

PART I. FINANCIAL INFORMATION

| | | |
|---------------|---|----|
| Item 1 | Condensed Consolidated Financial Statements | |
| | <u>Balance sheets as of September 30, 2009 (unaudited) and December 31, 2008</u> | 3 |
| | <u>Statements of operations for the three and nine months ended September 30, 2009 and 2008 (unaudited)</u> | 4 |
| | <u>Statements of cash flows for the nine months ended September 30, 2009 and 2008 (unaudited)</u> | 5 |
| | <u>Notes to condensed consolidated financial statements</u> | 7 |
| <u>Item 2</u> | <u>Management's Discussion and Analysis of Financial Conditions and Results of Operations</u> | 27 |
| <u>Item 4</u> | <u>Controls and Procedures</u> | 39 |

PART II. OTHER INFORMATION

| | | |
|---------------|--------------------------|----|
| <u>Item 1</u> | <u>Legal Proceedings</u> | 39 |
| <u>Item 6</u> | <u>Exhibits</u> | 39 |

| | | |
|-------------------|--|----|
| <u>Signatures</u> | | 40 |
|-------------------|--|----|

Table of Contents**PART I FINANCIAL INFORMATION****FINANCIAL STATEMENTS BIO-KEY INTERNATIONAL, INC. AND SUBSIDIARY
CONDENSED CONSOLIDATED BALANCE SHEETS**

| | September 30, 2009 (Unaudited) | December 31, 2008 |
|--|--------------------------------------|----------------------|
| ASSETS | | |
| Cash and cash equivalents | \$ 904,598 | \$ 1,712,912 |
| Accounts receivable, net of allowance for doubtful accounts of \$39,546 at September 30, 2009 and \$5,845 at December 31, 2008 | 174,917 | 96,131 |
| Inventory | 22,277 | 13,159 |
| Prepaid expenses | 56,127 | 54,843 |
| Continuing operations total current assets | 1,157,919 | 1,877,045 |
| Discontinued operations total current assets | 963,916 | 810,708 |
| Equipment and leasehold improvements, net | 52,614 | 25,677 |
| Deposits and other assets | 8,711 | 7,812 |
| Restricted cash | 40,500 | 40,500 |
| Intangible assets less accumulated amortization | 233,272 | 251,812 |
| Continuing operations total non-current assets | 335,097 | 325,801 |
| Discontinued operations non-current assets | 7,874,357 | 8,234,436 |
| TOTAL ASSETS | \$ 10,331,289 | \$ 11,247,990 |
| LIABILITIES | | |
| Accounts payable | \$ 416,212 | \$ 252,213 |
| Accrued liabilities | 892,882 | 663,567 |
| Note payable | 2,082,460 | |
| Deferred revenue | 199,786 | 677,966 |
| Continuing operations total current liabilities | 3,591,340 | 1,593,746 |
| Discontinued operations total current liabilities | 3,949,002 | 5,196,805 |
| Warrants | 152,451 | 12,317 |
| Redeemable preferred stock derivatives | 17,475 | 439 |
| Deferred revenue | 11,524 | |
| Continuing operations total non-current liabilities | 181,450 | 12,756 |
| Discontinued operations total non-current liabilities | 62,213 | 19,892 |
| TOTAL LIABILITIES | 7,784,005 | 6,823,199 |
| Commitments and contingencies | | |
| Series B redeemable convertible preferred stock: authorized, 1,000,000 shares (liquidation preference of \$1 per share); issued and outstanding 970,612 shares of \$.0001 par value at September 30, 2009 and 970,612 at December 31, 2008 | 469,550 | 1,008,224 |
| Series C redeemable convertible preferred stock: authorized, 600,000 shares (liquidation preference of \$10 per share); issued and outstanding 592,032 shares of \$.0001 par value at September 30, 2009 and 592,032 at December 31, 2008 | 4,063,666 | 6,498,516 |
| | 4,533,216 | 7,506,740 |
| STOCKHOLDERS DEFICIT: | | |
| Series A convertible preferred stock: authorized, 100,000 shares (liquidation preference of \$100 per share); issued and outstanding 30,557 shares of \$.0001 par value, at September 30, 2009 and December 31, 2008 | 3 | 3 |

Edgar Filing: BIO KEY INTERNATIONAL INC - Form 10-Q

| | | |
|---|----------------------|----------------------|
| Common stock authorized, 170,000,000 shares; issued and outstanding; 75,098,235 and 67,876,880 of \$.0001 par value at September 30, 2009 and December 31, 2008, respectively | 7,510 | 6,788 |
| Additional paid-in capital | 52,494,989 | 51,692,103 |
| Accumulated deficit | (54,488,434) | (54,780,843) |
| TOTAL STOCKHOLDERS DEFICIT | (1,985,932) | (3,081,949) |
| TOTAL LIABILITIES AND STOCKHOLDERS DEFICIT | \$ 10,331,289 | \$ 11,247,990 |

The accompanying notes to the condensed consolidated financial statements are an integral part of these statements.

Table of Contents

BIO-KEY INTERNATIONAL, INC. AND SUBSIDIARY
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

| | Three months ended September 30, | | Nine months ended September 30, | |
|---|-------------------------------------|-------------|------------------------------------|--------------|
| | 2009 | 2008 | 2009 | 2008 |
| Revenues | | | | |
| License fees and other | \$ 435,872 | \$ 394,807 | \$ 1,039,247 | \$ 1,889,156 |
| Service | 88,479 | 58,121 | 303,983 | 137,667 |
| | 524,351 | 452,928 | 1,343,230 | 2,026,823 |
| Costs and other expenses | | | | |
| Cost of license fees and other | 179,286 | 80,751 | 352,088 | 148,472 |
| Cost of Service | 15,499 | 17,540 | 48,208 | 36,911 |
| | 194,785 | 98,291 | 400,296 | 185,383 |
| Gross Profit | 329,566 | 354,637 | 942,934 | 1,841,440 |
| Operating Expenses | | | | |
| Selling, general and administrative | 749,771 | 863,240 | 2,474,986 | 2,639,630 |
| Research, development and engineering | 245,318 | 238,915 | 719,095 | 769,147 |
| | 995,089 | 1,102,155 | 3,194,081 | 3,408,777 |
| Operating loss | (665,523) | (747,518) | (2,251,147) | (1,567,337) |
| Other income (expenses) | | | | |
| Derivative and warrant fair value adjustments | (102,193) | 73,600 | (157,170) | 62,426 |
| Interest income | 405 | 42 | 405 | 1,339 |
| Interest expense | | (746) | | (3,419) |
| Investment Income | | 118,631 | | 118,631 |
| Other | (3,774) | (740) | (7,148) | (16,882) |
| | (105,562) | 190,787 | (163,913) | 162,095 |
| Loss from continuing operations | (771,085) | (556,731) | (2,415,060) | (1,405,242) |
| Income from discontinued operations | 701,674 | 511,763 | 2,707,468 | 612,861 |
| Net income (loss) | \$ (69,411) | \$ (44,968) | \$ 292,408 | \$ (792,381) |
| Basic and Diluted Earnings per Common Share: | | | | |
| Income (loss) from continuing operations | \$ (0.01) | \$ (0.02) | \$ (0.05) | \$ (0.04) |
| Income (loss) from discontinued operations | 0.01 | 0.01 | 0.04 | 0.01 |
| Net income (loss) | \$ 0.00 | \$ (0.01) | \$ (0.01) | \$ (0.03) |
| Weighted Average Shares Outstanding: | | | | |
| Basic | 73,521,550 | 64,913,843 | 71,115,231 | 63,299,532 |
| Diluted | 74,892,822 | 64,913,843 | 72,432,503 | 63,299,532 |

The accompanying notes to the condensed consolidated financial statements are an integral part of these statements.

Table of Contents

**BIO-KEY INTERNATIONAL, INC. AND SUBSIDIARY
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS**

(Unaudited)

| | Nine Months Ended September 30, | |
|--|---------------------------------|--------------|
| | 2009 | 2008 |
| CASH FLOW FROM OPERATING ACTIVITIES: | | |
| Net income (loss) | \$ 292,408 | \$ (792,381) |
| Less: | | |
| Income (loss) from discontinued operations | 2,707,468 | (612,861) |
| Loss from continuing operations | (2,415,060) | (1,405,242) |
| Adjustments to reconcile net loss to cash used in operating activities: | | |
| Derivative and warrant fair value adjustments | 157,170 | (62,426) |
| Depreciation | 17,875 | 15,547 |
| Amortization | | |
| Intangible assets | 18,540 | 9,444 |
| Allowance for doubtful receivables | 33,701 | 13,813 |
| Share-based compensation | 69,419 | 265,753 |
| Change in assets and liabilities: | | |
| Accounts receivable trade | (112,487) | 79,287 |
| Inventory | (9,118) | (12,008) |
| Prepaid expenses and other | (1,284) | 8,401 |
| Accounts payable | 163,999 | (287,331) |
| Accrued liabilities | 185,355 | (44,272) |
| Deferred revenue | (466,656) | (306,426) |
| Net cash used for continuing operations | (2,358,546) | (1,112,599) |
| Net cash provided by discontinued operations | 1,720,306 | 730,034 |
| Net cash used for operating activities | (638,240) | (382,565) |
| CASH FLOWS FROM INVESTING ACTIVITIES: | | |
| Capital expenditures | (25,085) | (1,361) |
| Deposits | (899) | (922) |
| Transfer of funds from restricted cash | | 112,594 |
| Proceeds from sale of assets | | 10,530 |
| Net cash provided by (used for) continuing operations | (25,984) | 120,841 |
| Net cash provided by (used for) discontinued operations | (24,423) | 414,247 |
| Net cash provided by (used for) investing activities | (50,407) | 535,088 |
| CASH FLOW FROM FINANCING ACTIVITIES: | | |
| Issuance of short-term obligations | 1,000,000 | |
| Repayment of long term obligations | (1,082,460) | |
| Dividend Payment | (37,207) | |
| Net cash used for financing activities | (119,667) | |
| NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS | (808,314) | 152,523 |
| CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD | 1,712,912 | 964,774 |
| CASH AND CASH EQUIVALENTS, END OF PERIOD | \$ 904,598 | \$ 1,117,297 |

Table of Contents

**BIO-KEY INTERNATIONAL, INC. AND SUBSIDIARY
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)**

SUPPLEMENTARY DISCLOSURES OF CASH FLOW INFORMATION

| | Nine Months Ended September 30, 2009 | 2008 |
|---|---|---------|
| Noncash Investing and Financing Activities: | | |
| Issuance of Debt in exchange of discounted Series B redeemable preferred Stock | 398,387 | |
| Discount on Series B redeemable preferred Stock | 130,153 | |
| Issuance of Debt in exchange of discounted Series C redeemable preferred Stock | 1,810,495 | |
| Discount on Series C redeemable preferred Stock | 591,487 | |
| Issuance of common stock through conversion of principal and dividends outstanding on preferred stock | 767,916 | 656,096 |

The accompanying notes to the condensed consolidated financial statements are an integral part of these statements.

Table of Contents

BIO-KEY INTERNATIONAL, INC. AND SUBSIDIARY

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2009 (Unaudited)

1. **BASIS OF PRESENTATION**

The accompanying unaudited interim condensed consolidated financial statements include the accounts of BIO-key International, Inc. and its wholly-owned subsidiary (collectively, the Company) and are stated in conformity with accounting principles generally accepted in the United States of America, pursuant to the rules and regulations of the Securities and Exchange Commission (the SEC). The operating results for interim periods are not necessarily indicative of results that may be expected for any other interim period or for the full year. Pursuant to such rules and regulations, certain financial information and footnote disclosures normally included in the financial statements have been condensed or omitted. Significant intercompany accounts and transactions have been eliminated in consolidation.

In the opinion of management, the accompanying unaudited interim consolidated financial statements contain all necessary adjustments, consisting only of those of a recurring nature, and disclosures to present fairly the Company's financial position and the results of its operations and cash flows for the periods presented. The balance sheet at December 31, 2008 was derived from the audited financial statements, but does not include all of the disclosures required by accounting principles generally accepted in the United States of America. These unaudited interim condensed consolidated financial statements should be read in conjunction with the financial statements and the related notes thereto included in the Company's Annual Report on Form 10-K for the year ended December 31, 2008 (the Form 10-K) filed on March 11, 2009.

Recently Issued Accounting Pronouncements

Adoption of New Accounting Standards

In June 2009, the FASB issued SFAS No. 168 *The FASB Accounting Standards Codification and the Hierarchy of Generally Accepted Accounting Principles - A Replacement of FASB Statement No. 162* (SFAS 168). SFAS 168 establishes the FASB Accounting Standards Codification™ (Codification) as the single source of authoritative U.S. generally accepted accounting principles (U.S. GAAP) recognized by the FASB to be applied by nongovernmental entities. Rules and interpretive releases of the SEC under authority of federal securities laws are also sources of authoritative U.S. GAAP for SEC registrants. SFAS 168 and the Codification are effective for financial statements issued for interim and annual periods ending after September 15, 2009. When effective, the Codification will supersede all existing non-SEC accounting and reporting standards. All other non-grandfathered, non-SEC accounting literature not included in the Codification will become non-authoritative. Following SFAS 168, the FASB will not issue new standards in the form of Statements, FASB Staff Positions, or Emerging Issues Task Force Abstracts. Instead, the FASB will issue Accounting Standards Updates, which will serve only to: (a) update the Codification; (b) provide background information about the guidance; and (c) provide the bases for conclusions on the change(s) in the Codification. The adoption of SFAS 168 did not have an impact on our consolidated financial statements.

In May 2009, the FASB issued SFAS No. 165, *Subsequent Events* (SFAS 165), which is now part of ASC 855, *Subsequent Events*. SFAS 165 sets forth the period after the balance sheet date during which management of a reporting entity should evaluate events or transactions that may occur for potential recognition or disclosure in the financial statements, the circumstances under which an entity should recognize events or transactions occurring after the balance sheet date in its financial statements, and the disclosures that an entity should make about events or transactions that occurred after the balance sheet date. SFAS 165 will be effective for interim or annual period ending after June 15, 2009 and will be applied prospectively. The Company has adopted the requirements of this pronouncement for this quarter ended June 30, 2009 and will evaluate subsequent events through the day of filing each financial statement.

Table of Contents

In April 2009, the FASB issued FSP No. FAS 115-2 and FAS 124-2, *Recognition and Presentation of Other-Than-Temporary Impairments* (FSP 115-2). Under the new guidance, which is now part of the Accounting Standards Codification (ASC) 320, *Investments - Debt and Equity Securities*, an other than-temporary impairment is recognized when an entity has the intent to sell a debt security or when it is more likely than not that an entity will be required to sell the debt security before its anticipated recovery in value. Additionally, the new guidance changes the presentation and amount of other-than-temporary impairment losses recognized in the income statement for instances in which the Company does not intend to sell a debt security, or it is more likely than not that the Company will not be required to sell a debt security prior to the anticipated recovery of its remaining cost basis. The Company separates the credit loss component of the impairment from the amount related to all other factors and reports the credit loss component in net realized investment gains (losses). The impairment related to all other factors if reported in accumulated other changes in equity from non-owner sources. In addition to the changes in measurement and presentation, the disclosures are required to be included in both interim and annual periods. The provisions of the new guidance were effective for interim periods ending after June 15, 2009. The adoption of the new guidance did not have a material effect on the Company's results of operations, financial position or liquidity and we will comply with the guidance going forward.

In April 2009, the FASB issued FSP No. FAS 107-1 and APB 28-1, *Interim Disclosures about Fair Value of Financial Instruments*, which is now part of ASC 825. This FSP essentially expands the disclosure about fair value of financial instruments that were previously required only annually to also be required for interim period reporting. In addition, the FSP requires certain additional disclosures regarding the methods and significant assumptions used to estimate the fair value of financial instruments. These additional disclosures were required beginning with the quarter ended June 30, 2009. The Company has adopted the requirements of this pronouncement effective the quarter ended June 30, 2009.

In February 2009, the Financial Accounting Standards Board (FASB) issued Statement of Financial Accounting Standards (SFAS) No. 141(R)-a, *Accounting for Assets Acquired and Liabilities Assumed in a Business Combination that Arise from Contingencies* (SFAS No. 141(R)-a), now part of ASC 805, which simplifies how entities will be required to account for contingencies arising in business combinations under SFAS 141(R) *Accounting for Business Combinations*. FASB decided to amend the guidance SFAS 141(R) to require assets acquired and liabilities assumed in a business combination that arise from contingencies be recognized at fair value, if fair value can be reasonably estimated. If fair value of such an asset or liability cannot be reasonably estimated, the asset or liability would be accounted for in accordance with FASB Statement No. 5 *Accounting for Contingencies* (SFAS 5). The provisions of SFAS No. 141(R)-a are applicable to business combinations consummated after January 1, 2009 for calendar year entities. The adoption of SFAS 141(R)-a will have an impact on the Company's accounting for business combinations in connection with any future acquisitions.

In December 2007, the FASB issued SFAS No. 160, *Non-controlling Interests in Consolidated Financial Statements - an amendment of ARB No. 51* (SFAS No. 160), which establishes accounting and reporting standards for the non-controlling interest in a subsidiary for the deconsolidation of a subsidiary. Under the guidance, which is now part of the (ASC) 810, *Consolidation*, SFAS No. 160 is effective for financial statements issued for fiscal years beginning after December 15, 2008, and interim statements within those fiscal years. The Company does not currently have any non-controlling interests.

In March 2008, the FASB issued SFAS No. 161, *Disclosures about Derivative Instruments and Hedging Activities*. (SFAS No.161) which amends and expands the disclosure requirements related to derivative instruments and hedging activities. Under the guidance, which is now part of the (ASC) 815, *Derivatives and Hedging Activities*, the Statement requires qualitative disclosures about objectives and strategies for using derivatives, quantitative disclosures about fair value amounts of and gains and losses on derivative instruments, and disclosures about credit-risk-related contingent features in derivative agreements. The provisions of SFAS 161 are effective for the fiscal year beginning January 1, 2009. The Company will comply with the disclosure requirements of this statement since it utilizes derivative instruments.

Table of Contents

In October 2008, the FASB issued Staff Position No. FAS 157-3, *Determining the Fair Value of a Financial Asset When the Market for That Asset is Not Active* (FSP 157-3). Under the guidance, which is now part of the (ASC) 350, *Intangibles - Goodwill and Other*, FSP 157-3 clarifies the application of SFAS 157, which the Company adopted as of January 1, 2008, in cases where a market is not active. The Company will comply with the clarification to the original application.

In November 2008, the FASB ratified the EITF consensus on Issue No. 08-7, *Accounting for Defensive Intangible Assets* (EITF 08-7). Under the guidance, which is now part of the (ASC) 350, *Intangibles - Goodwill and Other*, the consensus addresses the accounting for an intangible asset acquired in a business combination or asset acquisition that an entity does not intend to use or intends to hold to prevent others from obtaining access (a defensive intangible asset). Under EITF 08-7, a defensive intangible asset needs to be accounted as a separate unit of accounting and would be assigned a useful life based on the period over which the asset diminishes in value. EITF 08-7 was effective for transactions occurring after December 31, 2008. The Company will consider this standard in terms of intangible assets in connection with any future acquisitions.

Accounting Standards Not yet Adopted

In June 2009, the FASB issued SFAS No. 166 *Accounting for Transfers of Financial Assets* (SFAS 166). Statement 166 is a revision to FASB Statement No. 140, *Accounting for Transfers and Servicing of Financial Assets and Extinguishments of Liabilities* , and will require more information about transfers of financial assets, including securitization transactions, and where entities have continuing exposure to the risks related to transferred financial assets. It eliminates the concept of a qualifying special-purpose entity, changes the requirements for derecognizing financial assets, and requires additional disclosures. SFAS 166 enhances information reported to users of financial statements by providing greater transparency about transfers of financial assets and an entity's continuing involvement in transferred financial assets. SFAS 166 will be effective at the start of a reporting entity's first fiscal year beginning after November 15, 2009. Early application is not permitted. We are currently evaluating the impact of adoption of SFAS 166 on the accounting for our convertible notes and related warrant liabilities. The Company does not expect that the provisions of the new guidance will have a material effect on its results of operations, financial position or liquidity.

In June 2009, the FASB issued SFAS No. 167 *Amendments to FASB Interpretation No. 46(R)* (SFAS 167). Statement 167 is a revision to FASB Interpretation No. 46 (Revised December 2003), *Consolidation of Variable Interest Entities* , and changes how a reporting entity determines when an entity that is insufficiently capitalized or is not controlled through voting (or similar rights) should be consolidated. The determination of whether a reporting entity is required to consolidate another entity is based on, among other things, the other entity's purpose and design and the reporting entity's ability to direct the activities of the other entity that most significantly impact the other entity's economic performance. SFAS 167 will require a reporting entity to provide additional disclosures about its involvement with variable interest entities and any significant changes in risk exposure due to that involvement. A reporting entity will be required to disclose how its involvement with a variable interest entity affects the reporting entity's financial statements. SFAS 167 will be effective at the start of a reporting entity's first fiscal year beginning after November 15, 2009. Early application is not permitted. We are currently evaluating the impact, if any, of adoption of SFAS 167 on our financial statements.

2. LIQUIDITY AND CAPITAL RESOURCE MATTERS

We have incurred significant losses to date, and at September 30, 2009, we had an accumulated deficit of approximately \$54.5 million. The potential for significant growth of the Company as a whole is largely

Table of Contents

dependent upon market development and market acceptance of our biometric technology.

If the Company is unable to generate revenues as planned, we will need to obtain additional third-party financing to (i) conduct the sales, marketing and technical support necessary to execute our plan to substantially grow operations, increase revenue and serve a significant customer base; and (ii) provide working capital. No assurance can be given that any form of additional financing will be available on terms acceptable to the Company, that adequate financing will be obtained by the Company in order to meet its needs, or that such financing would not be dilutive to existing shareholders.

The accompanying condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, which contemplate continuation of the Company as a going concern, and assumes continuity of operations, realization of assets and the satisfaction of liabilities and commitments in the normal course of business. Recoverability of a major portion of the recorded asset amounts shown in the accompanying balance sheets is dependent upon the Company's ability to meet its financing requirements on a continuing basis, and maintain profitability in its future operations. The accompanying condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded assets or the amounts and classification of liabilities that might be necessary should the Company be unable to continue in existence.

3. DISCONTINUED OPERATIONS

Law Enforcement Division

On August 13, 2009, the Company and InterAct911 Mobile Systems, Inc. (the Buyer), a wholly-owned subsidiary of InterAct911 Corporation (the Parent), entered into an Asset Purchase Agreement (the Purchase Agreement), pursuant to which the Buyer agreed to purchase the Company's Law Enforcement division (the Business). The Buyer will pay the Company an aggregate purchase price of \$11 million for the Business, of which \$7 million is payable in cash at the closing of the transactions contemplated by the Purchase Agreement (the Asset Sale), subject to customary adjustments provided in the Purchase Agreement, and Buyer will issue a promissory note (the Note) in the original principal amount of \$4 million in favor of the Company. The Note is to be paid in three equal annual installments beginning on the first anniversary of the closing and will bear interest, payable on a quarterly basis, at a rate per annum equal to six percent (6%) compounded annually on the principal sum from time to time outstanding. The Note will be guaranteed by the Parent and its owner SilkRoad Equity, LLC (SilkRoad), a private investment firm, and secured by all of the intellectual property assets of the Business being transferred to the Buyer as part of the Asset Sale. In addition, at the closing of the Asset Sale, the Company will issue to SilkRoad a warrant to purchase up to 8 million shares of the Company's common stock at a cash purchase price of \$0.30 per share. This warrant will expire on the fifth anniversary of the closing.

The Purchase Agreement provides for Buyer to acquire substantially all of the assets relating to the Business, including the Company's customer contracts, intellectual property, accounts receivables, equipment, inventories, software, technologies, and communication systems relating to the Business, and to assume certain specified liabilities as set forth in the Purchase Agreement. The Company and InterAct Public Safety Systems, an affiliate of Buyer, have collaborated on many projects in the past, including partnership arrangements in which products used in the Business (including elements of the MobileCop®, PocketCop®, MobileRescue, MobileOffice, and InfoServer product lines) have been integrated with those of InterAct Public Safety Systems and sold to law enforcement agencies and other emergency response customers. Outside of those commercial dealings, there are no material relationships among the Company and Buyer or any of their respective affiliates other than in respect of the Purchase Agreement and the related ancillary agreements.

Edgar Filing: BIO KEY INTERNATIONAL INC - Form 10-Q

The assets and the liabilities for the Law Enforcement Division for the periods ended September 30, 2009 and December 31, 2008 were as follows:

Edgar Filing: BIO KEY INTERNATIONAL INC - Form 10-Q

Table of Contents

| | September 30, 2009 (Unaudited) | December 31, 2008 (Unaudited) |
|--|--------------------------------------|-------------------------------------|
| ASSETS | | |
| Accounts receivable, net of allowance for doubtful accounts of \$8,571 at September 30, 2009 and \$76,553 at December 31, 2008 | \$ 929,090 | \$ 624,891 |
| Costs in Excess of Billing | | 144,551 |
| Prepaid expenses | 34,826 | 41,266 |
| Total current assets | 963,916 | 810,708 |
| Equipment and leasehold improvements, net | 36,907 | 66,561 |
| Intangible assets less accumulated amortization | 464 | 330,889 |
| Goodwill | 7,836,986 | 7,836,986 |
| Non-current assets | 7,874,357 | 8,234,436 |
| TOTAL ASSETS | \$ 8,838,273 | \$ 9,045,144 |
| LIABILITIES | | |
| Accounts payable | \$ 81,575 | \$ 28,781 |
| Accrued liabilities | 269,185 | 638,322 |
| Note payable | | 1,516,651 |
| Deferred rent | 20,864 | 6,541 |
| Deferred revenue | 3,577,378 | 3,006,510 |
| Total current liabilities | 3,949,002 | 5,196,805 |
| Deferred rent | 31,652 | 11,510 |
| Deferred revenue | 30,561 | 8,382 |
| Total non-current liabilities | 62,213 | 19,892 |
| TOTAL LIABILITIES | \$ 4,011,215 | \$ 5,216,697 |

The closing of the Asset Sale is conditioned upon the Company's receipt of the approval of its stockholders as well as the satisfaction of certain other customary closing conditions. The Purchase Agreement may be terminated by either the Company or Buyer if the closing has not occurred by January 31, 2010 or upon the occurrence of certain customary events as set forth in the Purchase Agreement. The Company currently expects to hold a special meeting of its stockholders and that, if the stockholders approve the Asset Sale and the other conditions are satisfied, the Asset Sale would close during the fourth quarter of 2009. In addition, if the Purchase Agreement is terminated under certain circumstances, including a determination by the Company's Board of Directors to accept an acquisition proposal it deems superior to the Asset Sale, the Company has agreed to pay Buyer a termination fee equal to \$1 million.

Prior to the Purchase Agreement, the Business had been reported as a separate segment. The Business has been reported as a discontinued operation and all periods presented have been recast accordingly to reflect these operations as discontinued.

Revenues and net income for the Law Enforcement Business Segment for the three and nine month periods ended September 30, 2009 and 2008 were as follows:

| | Three Months Ended September 30, | | Nine Months Ended September 30, | |
|------------|-------------------------------------|--------------|------------------------------------|--------------|
| | 2009 | 2008 | 2009 | 2008 |
| Revenues | \$ 2,171,869 | \$ 2,429,803 | \$ 7,157,698 | \$ 6,976,279 |
| Net income | \$ 701,674 | \$ 511,763 | \$ 2,707,468 | \$ 678,314 |

Fire Division

On May 22, 2007, the Company and ZOLL Data Systems, Inc. (ZOLL), a subsidiary of ZOLL Medical Corporation, entered into an Asset Purchase Agreement (the Purchase Agreement), pursuant to which

Table of Contents

ZOLL acquired substantially all of the assets related to the Company's Fire/EMS Services division (the Fire Segment or Fire).

At the closing of the sale, the Company received approximately \$1.8 million in cash, which represented the purchase price of \$7 million, less closing adjustments of approximately \$4.3 million, which was paid to the Senior Noteholder (see Note 9), approximately \$450,000, which was paid to the leaseholder of the Company's premises, \$400,000, which was placed in escrow pursuant to the Purchase Agreement, and approximately \$40,000 credited to Zoll on the assumption of certain liabilities.

During the quarter ended September 30, 2007, \$250,000 of the escrow balance was released to ZOLL. The remaining escrow balance was remitted to the Company on May 6, 2008. From the remaining balance, \$50,000 was paid as a settlement of a customer claim associated with the discontinued Fire business, and \$15,454 was paid as related professional fees to settle the claim which resulted in the \$65,454 loss.

Prior to the sale, Fire had been reported as a separate segment. The Company sold its Fire operating segment to better focus on its core lines of business. The Fire business has been reported as a discontinued operation and all periods presented have been recast accordingly to reflect these operations as discontinued.

Revenues and net income (loss) for the Fire Segment for the three and nine month periods ended September 30, 2009 and 2008 were as follows:

| | Three Months Ended September 30, | | Nine Months Ended September 30, | |
|----------|-------------------------------------|------|------------------------------------|-------------|
| | 2009 | 2008 | 2009 | 2008 |
| Revenues | \$ | \$ | \$ | \$ |
| Net loss | \$ | \$ | \$ | \$ (65,454) |

4. SHARE BASED COMPENSATION

The Company accounts for share based compensation by measuring compensation cost for all stock awards at fair value on date of grant and recognition of compensation over the service period for awards expected to vest. The majority of our share-based compensation arrangements vest over either three or four years. The Company expenses its share-based compensation under the ratable method, which treats each vesting tranche as if it were an individual grant. The fair value of stock options is determined using the Black-Scholes valuation model, and requires the input of highly subjective assumptions. These assumptions include estimating the length of time employees will retain their vested stock options before exercising them (the expected option term), the estimated volatility of our common stock price over the option's expected term, the risk-free interest rate over the option's expected term, and the Company's expected annual dividend yield. Changes in these subjective assumptions can materially affect the estimate of fair value of stock-based compensation and consequently, the related amount recognized as an expense in the consolidated statements of operations. As required under the accounting rules, we review our valuation assumptions at each grant date and, as a result, are likely to change our valuation assumptions used to value employee stock-based awards granted in future periods. The values derived from using the Black-Scholes model are recognized as expense over the service period, net of estimated forfeitures (the number of individuals that will ultimately not complete their vesting requirements). The estimation of stock awards that will ultimately vest requires significant judgment. We consider many factors when estimating expected forfeitures, including types of awards, employee class, and historical experience. Actual results, and future changes in estimates, may differ substantially from our current estimates.

The compensation expense increased the Company's loss from continuing operations by \$9,651 and \$28,291 with no effect per share (basic and diluted) for the three months ended September 30, 2009 and 2008 respectively, and \$69,419 and \$265,753 with no effect per share (basic and diluted), for the nine months ended September 30, 2009 and 2008 respectively.

Edgar Filing: BIO KEY INTERNATIONAL INC - Form 10-Q

Table of Contents

The following table presents share-based compensation expenses for continuing operations included in the Company's unaudited condensed interim consolidated statements of operations:

| | Three Months Ended September 30, 2009 | | Three Months Ended September 30, 2008 | |
|---------------------------------------|--|-------|--|--------|
| Selling, general and administrative | \$ | 2,526 | \$ | 22,699 |
| Research, development and engineering | | 7,125 | | 5,592 |
| | \$ | 9,651 | \$ | 28,291 |

| | Nine Months Ended September 30, 2009 | | Nine Months Ended September 30, 2008 | |
|---------------------------------------|---|--------|---|---------|
| Selling, general and administrative | \$ | 51,427 | \$ | 253,019 |
| Research, development and engineering | | 17,992 | | 12,734 |
| | \$ | 69,419 | \$ | 265,753 |

Valuation Assumptions for Stock Options

For the three months ended September 30, 2009 and 2008, 0 and 195,000 stock options were granted, respectively. For the nine months ended September 30, 2009 and 2008, 790,000 and 759,272 stock options were granted, respectively. The fair value of each option was estimated on the date of grant using the Black-Scholes option-pricing model with the following assumptions:

| | Three Months Ended September 30, | |
|-------------------------------------|---|-------------|
| | 2009 | 2008 |
| Risk free interest rate | | 3.09% |
| Expected life of options (in years) | | 4.5 |
| Expected dividends | | 0% |
| Volatility of stock price | | 87% |

| | Nine Months Ended September 30, | |
|-------------------------------------|--|-------------|
| | 2009 | 2008 |
| Risk free interest rate | 1.83-1.85% | 2.95-3.72% |
| Expected life of options (in years) | 4.5 | 4.5 |
| Expected dividends | 0% | 0% |
| Volatility of stock price | 87% | 87-88% |

The stock volatility for each grant is determined based on the review of the experience of the weighted average of historical daily price changes of the Company's common stock over the expected option term. The expected term was determined using the simplified method for estimating expected option life, which qualify as "plain-vanilla" options; and the risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods corresponding with the expected life of the option.

Table of Contents

EQUITY COMPENSATION PLAN INFORMATION

1996 Stock Option Plan

During 1996, the Board of Directors and stockholders of the Company adopted the 1996 Stock Option Plan (the 1996 Plan). Under the 1996 Plan, 750,000 shares of common stock are reserved for issuance to employees, officers, directors, and consultants of the Company at exercise prices which may not be below 100% of fair market value for incentive stock options and 50% for all others. The term of stock options granted may not exceed ten years. Options issued under the 1996 Plan vest pursuant to the terms of stock option agreements with the recipients. In the event of a change in control, as defined, all options outstanding vest immediately. The 1996 Plan expired in May 2005.

1999 Stock Option Plan

During 1999, the Board of Directors of the Company adopted the 1999 Stock Option Plan (the 1999 Plan). The 1999 Plan was not presented to stockholders for approval and thus incentive stock options are not available under the plan. Under the 1999 Plan, 2,000,000 shares of common stock are reserved for issuance to employees, officers, directors, and consultants of the Company at exercise prices which may not be below 85% of fair market value. The term of non-statutory stock options granted may not exceed ten years. Options issued under the 1999 Plan vest pursuant to the terms of stock option agreements with the recipients. In the event of a change in control, as defined, all options outstanding vest immediately. The 1999 Plan expired in August 2009.

2004 Stock Option Plan

On October 12, 2004, the Board of Directors of the Company approved the 2004 Stock Option Plan (the 2004 Plan). The 2004 Plan has not yet been presented to stockholders for approval and thus incentive stock options are not available under this plan. Under the terms of the 2004 Plan, 4,000,000 shares of common stock are reserved for issuance to employees, officers, directors, and consultants of the Company at exercise prices which may not be below 85% of fair market value. The term of stock options granted may not exceed ten years. Options issued under the 2004 Plan vest pursuant to the terms of stock option agreements with the recipients. In the event of a change in control, as defined, all options outstanding vest immediately. The 2004 Plan expires in October 2014.

Non-Plan Stock Options

Periodically, the Company has granted options outside of the 1996, 1999, and 2004 Plans to various employees and consultants. In the event of change in control, as defined, certain of the non-plan options outstanding vest immediately.

Stock Option Activity

The following table summarizes stock option activity for the nine months ended September 30, 2009:

Edgar Filing: BIO KEY INTERNATIONAL INC - Form 10-Q

Table of Contents

| | 1996 Plan | 1999 Plan | Number of Options | | Total | Weighted average exercise price | Weighted average remaining life (in years) | Aggregate intrinsic value |
|---|---------------|----------------|-------------------|------------------|------------------|---------------------------------|--|---------------------------|
| | | | 2004 Plan | Non Plan | | | | |
| Outstanding, as of December 31, 2008 | 80,000 | 335,000 | 2,837,941 | 3,755,000 | 7,007,941 | \$ 0.78 | | |
| Granted | | 500,000 | 290,000 | | 790,000 | 0.087 | | |
| Exercised | | | | | | | | |
| Forfeited | | | (79,008) | | (79,008) | 0.47 | | |
| Expired | | (200,000) | (443,492) | (300,000) | (593,492) | 0.73 | | |
| Outstanding, as of September 30, 2009 | 80,000 | 635,000 | 2,605,441 | 3,455,000 | 6,775,441 | \$ 0.71 | 3.10 | \$ 136,013 |
| Vested or expected to vest at September 30, 2009 | | | | | 6,646,924 | \$ 0.72 | 3.04 | \$ 125,508 |
| Exercisable at September 30, 2009 | | | | | 6,245,938 | \$ 0.76 | 2.86 | \$ 93,834 |

The options outstanding and exercisable at September 30, 2009 were in the following exercise price ranges:

| Range of exercise prices | Options Outstanding | | | Options Exercisable | | |
|--------------------------|---------------------|---------------------------------|--|---------------------|---------------------------------|--|
| | Number of shares | Weighted average exercise price | Weighted average remaining life (in years) | Number exercisable | Weighted average exercise price | |
| \$ 0.075-0.21 | 1,596,272 | \$ 0.11 | 5.99 | 1,075,103 | \$ 0.11 | |
| 0.22-0.40 | 236,000 | 0.38 | 1.65 | 236,000 | 0.38 | |
| 0.41-0.68 | 1,584,000 | 0.58 | 2.02 | 1,575,666 | 0.58 | |
| 0.69-1.11 | 1,842,669 | 0.89 | 2.90 | 1,842,669 | 0.89 | |
| 1.12-1.62 | 1,516,500 | 1.30 | 1.66 | 1,516,500 | 1.30 | |
| \$ 0.075-1.62 | 6,775,441 | | | 6,245,938 | | |

The aggregate intrinsic value in the table above represents the total intrinsic value, based on the Company's closing stock price of \$0.195 as of September 30, 2009, which would have been received by the option holders had all option holders exercised their options as of that date. The total number of in-the-money options exercisable as of September 30, 2009 was 1,055,104.

The weighted average fair value of options, granted during the three months ended September 30, 2008 was \$0.11 per share, and during the nine months ended September 30, 2009 and September 30, 2008 was \$0.087 and \$0.11 per share, respectively.

As of September 30, 2009 future compensation cost related to nonvested stock options is approximately \$34,143 and will be recognized over an estimated weighted average period of approximately 0.97 years.

5. EARNINGS (LOSS) PER SHARE COMMON STOCK (EPS)

The Company's basic EPS is calculated using net income (loss) available to common shareholders and the weighted-average number of shares outstanding during the reporting period. Diluted EPS includes the effect from potential issuance of common stock, such as stock issuable pursuant to the exercise of stock

Edgar Filing: BIO KEY INTERNATIONAL INC - Form 10-Q

Table of Contents

options and warrants and the assumed conversion of convertible notes and preferred stock. For the three and nine months ended September 30, 2009 and 2008, diluted per share computations are not presented since this effect would be antidilutive.

The reconciliation of the numerators of the basic and diluted EPS calculations was as follows for both of the following three and nine month periods ended September 30:

| | Three Months ended September 30, | | Nine Months ended September 30, | |
|---|-------------------------------------|----------------|------------------------------------|----------------|
| | 2009 | 2008 | 2009 | 2008 |
| Numerator: | | | | |
| Loss from continuing operations | \$ (771,085) | \$ (556,731) | \$ (2,415,060) | \$ (1,405,242) |
| Convertible preferred stock dividends and accretion | (244,249) | (474,358) | (971,502) | (1,416,145) |
| Loss available to common stockholders (basic EPS) | \$ (1,015,334) | \$ (1,031,089) | \$ (3,386,562) | \$ (2,821,387) |

The following table summarizes the potential weighted average shares of common stock that were excluded from the diluted per share calculation, because the effect of including these potential shares was antidilutive.

| | Three Months Ended September 30, | | Nine Months Ended September 30, | |
|---------------------------------|-------------------------------------|------------|------------------------------------|------------|
| | 2009 | 2008 | 2009 | 2008 |
| Preferred Stock | 23,533,567 | 33,155,440 | 23,533,567 | 33,155,440 |
| Stock Options | 1,371,272 | 564,272 | 1,317,272 | 564,272 |
| Potentially dilutive securities | 24,904,839 | 33,719,712 | 24,850,839 | 33,719,712 |

Items excluded from the diluted per share calculation because the exercise price was greater than the average market price of the common shares:

| | Three Months Ended September 30, | | Nine Months Ended September 30, | |
|---------------|-------------------------------------|------------|------------------------------------|------------|
| | 2009 | 2008 | 2009 | 2008 |
| Stock options | 5,404,169 | 7,053,669 | 5,458,169 | 7,053,669 |
| Warrants | 3,775,791 | 10,566,375 | 3,775,791 | 10,566,375 |
| Total | 9,179,960 | 17,620,044 | 9,233,960 | 17,620,044 |

Table of Contents

6. EQUIPMENT AND LEASEHOLD IMPROVEMENTS

Equipment and leasehold improvements consisted of the following:

| | September 30, 2009 | December 31, 2008 |
|--|-----------------------|----------------------|
| Equipment | \$ 363,844 | \$ 352,740 |
| Furniture and fixtures | 94,402 | 87,972 |
| Software | 72,575 | 72,575 |
| Leasehold improvements | 33,812 | 24,382 |
| | 564,633 | 537,669 |
| Less accumulated depreciation and amortization | (512,019) | (511,992) |
| Total | \$ 52,614 | \$ 25,677 |

7. GOODWILL AND OTHER INTANGIBLE ASSETS

The Company's goodwill resulted from the acquisition of Public Safety Group, Inc. and certain assets and assumed liabilities of the Mobile Government Division of Aether Systems, Inc. in 2004. The Company has elected to perform the annual assessment of the carrying value of all goodwill as of September 30th of each year using a number of criteria, including the value of the overall enterprise. Impairment charges from existing operations or other acquisitions, if any, are reflected as an operating expense in the statement of operations. As of September 30, 2009 we have performed our testing which resulted in no impairment. As of September 30, 2009 and December 31, 2008, all goodwill was associated with the Law Enforcement Business.

Other intangible assets as of September 30, 2009 consisted of the following:

| | September 30, 2009 | | | December 31, 2008 | | |
|-----------------------------|-----------------------------|-----------------------------|------------------------|-----------------------------|-----------------------------|------------------------|
| | Gross Carrying Amount | Accumulated Amortization | Net Carrying Amount | Gross Carrying Amount | Accumulated Amortization | Net Carrying Amount |
| Patents and patents pending | 287,248 | (53,976) | 233,272 | 297,101 | (45,448) | 251,653 |
| Total | \$ 287,248 | \$ (53,976) | \$ 233,272 | \$ 297,101 | \$ (45,448) | \$ 251,653 |

Aggregate amortization expense for the three months ended September 30, 2009 and 2008, was \$2,946 and \$5,455 respectively, and was \$8,528 and \$9,444 for the nine months ended September 30, 2009 and 2008 respectively.

8. **RESTRICTED CASH**

During 2008, the Company extended its property lease at the Marlborough, MA location. Pursuant to the agreement BIO-key was to maintain a security deposit in the form of an irrevocable letter of credit in the amount of \$40,500. However, BIO-key and the landlord for the property subsequently agreed to have BIO-key place the funds in a third party escrow account, to be returned at the conclusion of the lease term, in

Table of Contents

August 2011. The escrow is recorded as the non-current asset restricted cash as at September 30, 2009 and December 31, 2008.

9. NOTES PAYABLE, CONVERTIBLE DEBT FINANCING / WARRANTS

Notes Payable

Notes Payable consisted of the following:

| | September 30, 2009 | December 31, 2008 |
|---------------|-----------------------|----------------------|
| Notes payable | \$ 2,082,460 | \$ |

Effective as of July 2, 2009, the Company entered into a Settlement and Mutual Release Agreement (the *Settlement Agreement*) with Longview Special Finance, Inc. and Longview Fund, L.P. (collectively, the *Longview Entities*) in order to resolve all matters relating to the litigation initiated by the Longview Entities earlier this year, in which they were seeking \$2,886,563 in damages and an unspecified amount of interest and attorney's fees from the Company as a result of the Company's alleged improper failure to redeem their outstanding shares of the Company's Convertible Preferred Stock (collectively, the *Shares*) in accordance with the terms and conditions of such preferred stock. Pursuant to the Settlement Agreement, without admission of any liability or fault, the parties agreed to a payment schedule under which the Company is required to pay a total cash settlement amount of \$2,164,922, fifty percent (50%) of which was paid on July 7, 2009. The remaining portion of the settlement amount will bear interest at seventeen percent (17%) per annum and was required to be paid in full on or before October 30, 2009. In return, the Longview Entities agreed to a full and complete release of the Company from all claims that were or could have been alleged in the lawsuit and agreed to relinquish all of the Shares upon receiving final payment of the settlement amount. From October 30, 2009 until November 12, 2009, interest on the remaining portion of the settlement amount accrued at twenty percent (20%) per annum. On November 12, 2009, the Company paid in full the entire outstanding portion of the settlement amount, together with all accrued and unpaid interest, and satisfied all of its obligations to the Longview Entities under the Settlement Agreement.

On July 7, 2009, the Company issued an unsecured promissory note (the *Note*) in the aggregate principal amount of \$1,000,000 to the Shaar Fund, Ltd (*Shaar*). The Note bears interest at eight percent (8%) per annum and was originally due and payable on November 4, 2009. Shaar has extended the due date of the Note to the earlier to occur of (i) the fifth business day after the closing of the Asset Sale (as defined below) and (ii) January 31, 2010 pursuant to a Note Amendment and Extension Agreement dated as of November 3, 2009 between the Company and Shaar, has also made a bridge loan to the Company in the principal amount of \$750,000, evidenced by the Company's unsecured Six Percent (6%) Promissory Note dated as of November 12, 2009.

In consideration thereof, Shaar and the Company also entered into a Securities Exchange Agreement dated as of November 12, 2009 (the *Exchange Agreement*), pursuant to which the Company and the holders of the outstanding shares of the Company's Series A Convertible Preferred Stock, \$0.0001 par value per share (the *Series A Preferred Stock*), such holders being Shaar (27,932 shares) and Thomas J. Colatosti (2,625 shares), agreed to exchange (a) their shares of Series A Preferred Stock for an equal number of shares of the Company's Series D Convertible Preferred Stock, \$0.0001 par value per share (the *Series D Preferred Stock*), and Warrants to purchase up to an aggregate of 5,000,000 shares of the Company's Common Stock, including up to 4,750,000 shares to Shaar and up to 250,000 shares to Mr. Colatosti, at an exercise price of \$0.30 per share, and (b) all dividends accrued and unpaid on their shares of Series A Preferred Stock for Seven Percent (7%)

Edgar Filing: BIO KEY INTERNATIONAL INC - Form 10-Q

Convertible Promissory Notes (the Convertible Notes). The Series D Preferred Stock is mandatorily redeemable on December 31, 2010, at which time the Company is to redeem for cash all outstanding shares at \$100 per share, together with all accrued and unpaid dividends thereon.

Table of Contents

The Convertible Notes may be converted in whole or in part at any time at the option of the holder into shares of the Company's Common Stock at a price equal to the lower of (i) the average closing price of the Common Stock as quoted by Bloomberg for the ten (10) trading days prior to the date that the notice of conversion is transmitted to the Company, and (ii) \$0.30, subject to certain adjustments. The closing of the transactions contemplated by the Exchange Agreement is conditioned upon, among other things, the closing of the Asset Sale.

Convertible Debt Financing/Warrants

Long-term obligations consisted of the following as of:

| | September 30, 2009 | December 31, 2008 |
|-----------------|-----------------------|----------------------|
| 2004 | | |
| FMV of warrants | \$ | \$ 291 |
| 2005 | | |
| FMV of warrants | 96,649 | 6,666 |
| 2006 | | |
| FMV of warrants | 55,802 | 5,360 |
| Total | \$ 152,451 | \$ 12,317 |

Senior Convertible Term Notes

The account balance shown represents the fair market value of warrants issued in conjunction with debt offerings undertaken from the 2004 to 2006 fiscal years. The Warrants are classified as liabilities and were valued using the Black Scholes Option Pricing model with the following assumptions:

| | September 30, 2009 | December 31, 2008 |
|-------------------------|-----------------------|----------------------|
| Dividend Yield | 0% | 0% |
| Annual volatility | 157-170% | 112-121% |
| Risk-free interest rate | 0.18-0.70% | 0.32-0.78% |

2004 and 2005 Senior Note Derivatives and Discounts

The 2004 and 2005 Senior Notes contained features that were considered embedded derivative financial instruments, such as: Principal's conversion option, Monthly Payments Conversion Option, Interest Rate Adjustment provision, and the Default provision. These features were bifurcated and recorded on the Company's balance sheet at their fair value.

Table of Contents

10. ACCRUED LIABILITIES

Accrued liabilities consisted of the following:

| | September 30, 2009 | December 31, 2008 |
|--|-----------------------|----------------------|
| Contract costs not yet invoiced by vendors | \$ 68,866 | \$ 105,788 |
| Compensation | 52,158 | 48,030 |
| Compensated absences | 140,556 | 130,433 |
| Royalties | 206,443 | 33,402 |
| Interest | 194,972 | 176,083 |
| Other | 229,887 | 169,831 |
| Total | \$ 892,882 | \$ 663,567 |

11. REDEEMABLE PREFERRED STOCK

Series B Convertible Preferred Stock

The Company issued 1,000,000 shares of redeemable Series B Convertible Preferred Stock on February 23, 2006, upon the conversion of certain convertible term notes. Each share of Series B Preferred Stock has an Original Issue Price of \$1.00 per share. The holder has the option to redeem the shares of Series B Preferred Stock at any time for a number of shares of the Company's common stock equal to the Original Issue Price plus accumulated and unpaid dividends divided by the fixed conversion price of \$0.30 per share of Common Stock. The conversion price is subject to adjustment if common stock is issued by the Company subsequent to the original issue date of the Series B preferred stock, except for other conversions, options, warrants, dividends paid in stock or pursuant to an acquisition by the Company, at a price less than the conversion price. Mandatory conversion of all Series B shares will be automatic if, for the 30 trading days prior to January 1, 2009, the average closing bid price for one share of common stock is at least \$1.10. The shares shall be converted at the conversion price then in effect. If the average bid price for the 30 trading days prior to January 1, 2009 per common share is less than \$1.10 the Company shall mandatorily redeem all remaining outstanding Series B Preferred Stock by paying cash equal to \$1.00 per share with all accrued and unpaid dividends. The Company may, at its election, redeem any or all of the remaining outstanding Series B shares in cash at a conversion price equal to \$1.20 per share, together with all accrued and unpaid dividends upon giving 30 days' notice. Holders of the Series B Preferred Stock are entitled to cumulative, prior and in preference to holders of common stock dividends equal to 15% per annum of the Original Purchase Price still outstanding, payable quarterly. In any liquidation of the Company, each share of Preferred Stock is entitled to a liquidation preference on a pari passu basis with the Series A and Series C Preferred Stock before any distribution may be made on the Company's common stock.

The mandatory redemption features were triggered in January 2009 due to the passing of the applicable mandatory redemption dates and the price of the Company's common stock, as reported by the OTC Bulletin Board, trading below the applicable thresholds contained in the terms of the Preferred Stock. Absent a waiver from the holders of the Preferred Stock, the Company would therefore be required to redeem its outstanding shares of Preferred Stock, to the extent that the Company is legally permitted to do so, by paying cash to the holders of such shares in accordance with the terms of such Preferred Stock. The Company is continuing to accrue dividends at the default rate of 17%.

Edgar Filing: BIO KEY INTERNATIONAL INC - Form 10-Q

Effective as of July 2, 2009, the Company entered into an Agreement and redeemed 520,612 for a total cash settlement amount of \$390,459, fifty percent (50%) of which was paid on July 7, 2009. The remaining portion of the settlement amount will bear interest at seventeen percent (17%) per annum and is required to be paid in full on or before October 30, 2009. From October 30, 2009 until November 12, 2009, interest on the remaining portion of the settlement amount accrued at twenty percent (20%) per annum. On November 12, 2009, the Company paid in full the entire outstanding portion of the settlement amount, together with all accrued and unpaid interest, and satisfied all of its obligations to the Longview Entities under the Settlement Agreement.

As of September 30, 2009, 1,000,000 shares of Series B Preferred Stock were authorized, 970,612 of which

Table of Contents

were issued and outstanding, at a par value of \$0.0001 and a liquidation preference of \$1.00 with accumulated dividends in arrears of \$20,162, which have been accreted to the principal balance of the

The Preferred Stock contains features that are considered embedded derivative financial instruments: Preferred Stock's conversion option: The Preferred Stock is convertible at the Holder's option at any time at the fixed conversion price of \$0.30 per share; Quarterly Dividends Conversion Option: Holders have the option to convert the Stock's quarterly dividend payment at a conversion price of the average 10 days closing price prior to the dividend record date. These features have been bifurcated and recorded on the Company's balance sheet as liabilities at their fair value.

As of September 30, 2009 the derivatives were valued at \$2,059. Conversion related derivatives were valued using the Binomial Option Pricing Model with the following assumptions: dividend yield of 17%; annual volatility of 49%; and risk free annual interest rate of 0.14% as well as probability analysis related to trading volume restrictions.

Series C Convertible Preferred Stock

The Company issued 592,032 shares of redeemable Series C Convertible Preferred Stock on August 10, 2006, upon the exchange of certain convertible term notes. Each share of Series C Preferred Stock has an Original Issue Price of \$10.00 per share. The holder has the option to redeem the shares of Series C Preferred Stock at any time for a number of shares of the Company's common stock equal to the Original Issue Price plus accumulated and unpaid dividends divided by the fixed conversion price of \$0.30 per share of Common Stock. The conversion price is subject to adjustment if common stock is issued by the Company subsequent to the original issue date of the Series C Preferred Stock, except for other conversions, options, warrants, dividends paid in stock or pursuant to an acquisition by the Company, at a price less than the conversion price. Mandatory conversion of all Series C shares will be automatic if, for the 30 trading days prior to January 1, 2009, the average closing bid price for one share of common stock is at least \$1.20. The shares shall be converted at the conversion price then in effect. If the average bid price for the 30 trading days prior to January 1, 2009 per common share is less than \$1.20 the Company shall mandatorily redeem all remaining outstanding Series C Preferred Stock by paying cash equal to \$10.00 per share with all accrued and unpaid dividends. The Company may, at its election, redeem any or all of the remaining outstanding Series C shares in cash at a conversion price equal to \$12.00 per share, together with all accrued and unpaid dividends upon giving 30 days' notice. Holders of the Series C Preferred Stock are entitled to cumulative, prior and in preference to holders of common stock dividends equal to 15% per annum of the Original Purchase Price still outstanding, payable quarterly. In any liquidation of the Company, each share of Preferred Stock is entitled to a liquidation preference on a pari passu basis with the Series A and Series B Preferred Stock before any distribution may be made on the Company's common stock.

The mandatory redemption features were triggered in January 2009 due to the passing of the applicable mandatory redemption dates and the price of the Company's common stock, as reported by the OTC Bulletin Board, trading below the applicable thresholds contained in the terms of the Preferred Stock. Absent a waiver from the holders of the Preferred Stock, the Company would therefore be required to redeem its outstanding shares of Preferred Stock, to the extent that the Company is legally permitted to do so, by paying cash to the holders of such shares in accordance with the terms of such Preferred Stock. The Company is continuing to accrue dividends at the default rate of 17%.

Effective as of July 2, 2009, the Company entered into an Agreement and redeemed 236,595 for a total cash settlement amount of \$1,774,463, fifty percent (50%) of which was paid on July 7, 2009. The remaining portion of the settlement amount will bear interest at seventeen percent (17%) per annum and is required to be paid in full on or before October 30, 2009. From October 30, 2009 until November 12, 2009, interest on the remaining portion of the settlement amount accrued at twenty percent (20%) per annum. On November 12, 2009, the Company paid in full the entire outstanding portion of the settlement amount, together with all

Table of Contents

accrued and unpaid interest, and satisfied all of its obligations to the Longview Entities under the Settlement Agreement.

As of September 30, 2009, 600,000 Shares of Series C Preferred Stock were authorized, 592,032 of which were issued and outstanding, at a par value of \$0.0001 and a liquidation preference of \$10.00 with accumulated dividends in arrears of \$509,296, which have been accreted to the principal balance of the Series C Preferred Stock.

The Preferred Stock contains features that are considered embedded derivative financial instruments: Preferred Stock's conversion option: The Preferred Stock is convertible at the Holder's option at any time at the fixed conversion price of \$0.30 per share; Quarterly Dividends Conversion Option: Holders have the option to convert the Stock's quarterly dividend payment at a conversion price of the average 10 days closing price prior to the dividend record date. These features have been bifurcated and recorded on the Company's balance sheet as liabilities, at their fair value.

As of September 30, 2009 the derivatives were valued at \$15,416. Conversion related derivatives were valued using the Binomial Option Pricing Model with the following assumptions: dividend yield of 17%; annual volatility of 49%; and risk free annual interest rate of 0.14% as well as probability analysis related to trading volume restrictions.

12. STOCKHOLDERS DEFICIT

Common Stock

The Company is authorized to issue 170,000,000 shares of common stock, \$.0001 par value per share, of which 75,098,235 were issued and outstanding as of September 30, 2009.

Holders of common stock have equal rights to receive dividends when, as and if declared by the Board of Directors, out of funds legally available therefor. Holders of common stock have one vote for each share held of record and do not have cumulative voting rights.

Holders of common stock are entitled, upon liquidation of the Company, to share ratably in the net assets available for distribution, subject to the rights, if any, of holders of any preferred stock then outstanding. Shares of common stock are not redeemable and have no preemptive or similar rights. All outstanding shares of common stock are fully paid and nonassessable.

During the three months and the nine months ended September 30, 2009, preferred stockholders converted accumulated dividends of \$366,126 and \$809,833 into 2,448,139 shares and 7,221,355 shares of the Company's common stock, respectively.

Series A Convertible Preferred Stock

Within the limits and restrictions provided in the Company's Certificate of Incorporation, the Board of Directors has the authority, without further action by the shareholders, to issue up to 5,000,000 shares of preferred stock, \$.0001 par value per share, in one or more series, and to fix, as to any such series, any dividend rate, redemption price, preference on liquidation or dissolution, sinking fund terms, conversion rights, voting rights, and any other preference or special rights and qualifications.

In March 2004, we designated 100,000 shares of preferred stock as Series C Convertible Preferred Stock. In connection with the Company's reincorporation in Delaware on January 1, 2005, each share of Series C

Table of Contents

Convertible Preferred Stock was automatically converted into one share of Series A Convertible Preferred Stock (the Series A Shares), of which 30,557 were issued and outstanding September 30, 2009.

The Series A Shares accrue a cumulative annual dividend of 7% on the \$100 face amount of such shares payable June 15 and December 15 each year in shares of common stock. In the event of a liquidation, dissolution or winding up of the Company, the Series A shares have a liquidation preference of \$100 per share (plus all accrued and unpaid dividends thereon) prior to any payment or distribution to holders of our common stock. The Series A Shares are convertible into common stock at a conversion price of \$0.30 per share. The conversion price is subject to proportional adjustment in the event of stock splits, stock dividends or reclassifications. Subject to certain exceptions, in the event we issue additional shares of common stock at a purchase price less than the conversion price of the Series A Shares, the conversion price shall be lowered to such lesser price. In the event that the average closing bid price of our common stock is less than \$1.00 per share for thirty (30) consecutive trading days at any time after November 17, 2008, we will be required to redeem the Series A Shares by payment of \$100 per share plus all accrued and unpaid dividends due thereon.

The mandatory redemption features were triggered in January 2009 due to the passing of the applicable mandatory redemption dates and the price of the Company's common stock, as reported by the OTC Bulletin Board, trading below the applicable thresholds contained in the terms of the Preferred Stock. Absent a waiver from the holders of the Preferred Stock, the Company would therefore be required to redeem its outstanding shares of Preferred Stock, to the extent that the Company is legally permitted to do so, by paying cash to the holders of such shares in accordance with the terms of such Preferred Stock. The Company is continuing to accrue dividends at the default rate of 9%.

We are required to obtain the consent of the holders of a majority of the Series A Shares in order to, among other things, issue any shares of preferred stock that are equal to or have a preference over the Series A shares or issue any shares of preferred stock, rights, options, warrants, or any other securities convertible into common stock of the Company, other than those issued to employees of the Company in the ordinary course of their employment or to consultants or other persons providing services to the Company so long as such issuances do not exceed 500,000 shares of common stock. We are also required to obtain such consent in order to, among other things, complete a sale or other disposition of any material assets, complete an acquisition of a material amount of assets, engage in a merger, reorganization or consolidation, or incur or guaranty any indebtedness in excess of \$50,000.

As of September 30, 2009, cumulative dividends in arrears related to the Series A preferred stock were approximately \$669,969, which have been accreted to the principal balance of the Series A preferred stock.

Warrants

The Company has issued warrants to certain creditors, investors, investment bankers and consultants. A summary of warrant activity is as follows:

Table of Contents

| | Total Warrants | Weighted average exercise price | Weighted average remaining life (in years) | Aggregate intrinsic value |
|--|-------------------|--|--|---------------------------------|
| Outstanding, as of December 31, 2008 | 10,566,375 | \$ 0.95 | | |
| Granted | | | | |
| Exercised | | | | |
| Expired | (4,579,476) | \$ 1.30 | | |
| Outstanding, as of September 30, 2009 | 5,986,899 | \$ 0.65 | 0.85 | \$ |
| Vested or expected to vest at September 30, 2009 | 5,986,899 | \$ 0.65 | 0.85 | \$ |
| Exercisable at September 30, 2009 | 5,986,899 | \$ 0.65 | 0.85 | \$ |

The warrants outstanding and exercisable at September 30, 2009 were in the following exercise price ranges:

| Range of exercise prices | Warrants outstanding and Exercisable | |
|--------------------------|--------------------------------------|--|
| | Number of warrants | Weighted average remaining life (in years) |
| \$ 0.30 | 2,798,014 | 1.36 |
| 0.75 | 533,333 | 1.86 |
| 1.00 | 2,655,552 | .12 |
| | 5,986,899 | |

13. COMPREHENSIVE INCOME (LOSS)

The company does not have any components of accumulated other comprehensive income (loss) at September 30, 2009 and December 31, 2008.

The components of comprehensive income (loss) for the nine months ended September 30, 2009 and 2008 were as follows:

| | September 30, 2009 | September 30, 2008 |
|---|-----------------------|-----------------------|
| Net income (loss) | \$ 292,408 | \$ (792,382) |
| Unrealized gain on securities, net of tax | | 1,109 |
| Total comprehensive income (loss) | \$ 292,408 | \$ (791,273) |

14. SEGMENT INFORMATION

Edgar Filing: BIO KEY INTERNATIONAL INC - Form 10-Q

The Company has determined that its continuing operations are one discrete operating segment consisting of the Biometric products.

15. INCOME TAXES

The Company has a valuation allowance against the full amount of its net deferred taxes. The Company currently provides a valuation allowance against deferred taxes when it is more likely than not that some portion, or all of its deferred tax assets will not be realized.

Table of Contents

The Company has reduced its deferred tax assets and the associated valuation allowance for gross unrecognized tax affected benefits by approximately \$4,100,000. There was no adjustment to accumulated deficit as a result of these unrecognized tax benefits since there was a full valuation allowance against the related deferred tax assets. If these unrecognized tax benefits are ultimately recognized, they would have no impact on the effective tax rate due to the existence of the valuation allowance.

The Company has not been audited by the Internal Revenue Service (IRS) or any states in connection with income taxes. The Company files income tax returns in the U.S. federal jurisdiction and various state jurisdictions. The periods from 2006-2008 remain open to examination by the IRS and state jurisdictions. The Company believes it is not subject to any tax risk beyond the preceding discussion. The Company's policy is to recognize interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense. The Company does not have any accrued interest or penalty associated with any unrecognized tax benefits, nor was any significant interest expense recognized during the nine months ended September 30, 2009 and 2008.

16. SUBSEQUENT EVENTS

Effective as of July 2, 2009, the Company entered into a Settlement and Mutual Release Agreement (the Settlement Agreement) with Longview Special Finance, Inc. and Longview Fund, L.P. (collectively, the Longview Entities) in order to resolve all matters relating to the litigation initiated by the Longview Entities earlier this year, in which they were seeking \$2,886,563 in damages and an unspecified amount of interest and attorney's fees from the Company as a result of the Company's alleged improper failure to redeem their outstanding shares of the Company's Convertible Preferred Stock (collectively, the Shares) in accordance with the terms and conditions of such preferred stock. Pursuant to the Settlement Agreement, without admission of any liability or fault, the parties agreed to a payment schedule under which the Company is required to pay a total cash settlement amount of \$2,164,922, fifty percent (50%) of which was paid on July 7, 2009. The remaining portion of the settlement amount will bear interest at seventeen percent (17%) per annum and was required to be paid in full on or before October 30, 2009. In return, the Longview Entities agreed to a full and complete release of the Company from all claims that were or could have been alleged in the lawsuit and agreed to relinquish all of the Shares upon receiving final payment of the settlement amount. From October 30, 2009 until November 12, 2009, interest on the remaining portion of the settlement amount accrued at twenty percent (20%) per annum. On November 12, 2009, the Company paid in full the entire outstanding portion of the settlement amount, together with all accrued and unpaid interest, and satisfied all of its obligations to the Longview Entities under the Settlement Agreement.

On July 7, 2009, the Company issued an unsecured promissory note (the Note) in the aggregate principal amount of \$1,000,000 to the Shaar Fund, Ltd (Shaar). The Note will bear interest at eight percent (8%) per annum and was originally due and payable on November 4, 2009.

Shaar (a) has extended the due date of the Note to the earlier to occur of (i) the fifth business day after the closing of the Asset Sale (as defined below) and (ii) January 31, 2010 pursuant to a Note Amendment and Extension Agreement dated as of November 3, 2009 between the Company and Shaar, and (b) has made a bridge loan to the Company in the principal amount of \$750,000, evidenced by the Company's unsecured Six Percent (6%) Promissory Note dated as of November 12, 2009.

In consideration thereof, Shaar and the Company also entered into a Securities Exchange Agreement dated as of November 12, 2009 (the Exchange Agreement), pursuant to which the Company and the holders of the outstanding shares of the Company's Series A Convertible Preferred Stock, \$0.0001 par value per share (the Series A Preferred Stock), such holders being Shaar (27,932 shares) and Thomas J. Colatosti (2,625 shares), agreed to exchange (a) their shares of Series A Preferred Stock for an equal number of shares of the Company's Series D Convertible Preferred Stock, \$0.0001 par value per share (the Series D Preferred Stock), and Warrants to purchase up to an aggregate of 5,000,000 shares of the Company's Common Stock, including up to 4,750,000 shares to Shaar and up to 250,000 shares to Mr. Colatosti, at an

exercise

Table of Contents

price of \$0.30 per share, and (b) all dividends accrued and unpaid on their shares of Series A Preferred Stock for Seven Percent (7%) Convertible Promissory Notes (the "Convertible Notes"). The Series D Preferred Stock is mandatorily redeemable on December 31, 2010, at which time the Company is to redeem for cash all outstanding shares at \$100 per share, together with all accrued and unpaid dividends thereon. The Convertible Notes may be converted in whole or in part at any time at the option of the holder into shares of the Company's Common Stock at a price equal to the lower of (i) the average closing price of the Common Stock as quoted by Bloomberg for the ten (10) trading days prior to the date that the notice of conversion is transmitted to the Company, and (ii) \$0.30, subject to certain adjustments. The closing of the transactions contemplated by the Exchange Agreement is conditioned upon, among other things, the closing of the Asset Sale.

On October 23, 2009, in connection with seeking stockholder approval of the Asset Sale (reference Section 3 Asset Purchase Agreement (the "Purchase Agreement")), the Company has filed a proxy statement with the Securities and Exchange Commission. The stockholder meeting is scheduled for November 19, 2009.

In preparation for the Company's impending sale of its Law Enforcement Division and to incentivize employees, officers and directors of the remaining organization, on November 2, 2009, the Board of Directors of BIO-key International, Inc. (the "Company") authorized the Company to (i) cancel all outstanding options to acquire shares of the Company's common stock, \$0.0001 par value per share ("Common Stock"), held by officers, directors and employees of the Company and having an exercise price greater than \$0.30 per share granted under the Company's 2004 Stock Incentive Plan and grant the holders of such options new options to acquire shares of Common Stock with an exercise price equal to \$0.30 per share and covering a proportionately reduced number of shares of Common Stock relative to the existing exercise price, and (ii) offer to the holders of all outstanding options to acquire shares of Common Stock having an exercise price greater than \$0.30 granted under the Company's 1999 Stock Option Plan, the Company's 1996 Stock Option Plan, or under stock option agreements not subject to any of the Company's equity incentive plans, the opportunity to cancel such options and receive in exchange therefor new options to acquire shares of Common Stock under the respective plan or under stock option agreements not subject to any of the Company's equity incentive plans, in each case with an exercise price equal to \$0.30 per share and covering a proportionately reduced number of shares of Common Stock relative to the existing exercise price. As a result of these actions, the aggregate number of outstanding options to acquire Common Stock has been reduced from approximately 5.5 million to approximately 2.3 million, or approximately 60% of all vested options. The exercise prices of the cancelled options ranged from \$0.31 to \$1.62. The average exercise price has been reduced by approximately 60%, proportionally consistent with the reduction in the number of new options.

All of the outstanding options to acquire shares of Common Stock having an exercise price greater than \$0.30 per share were fully vested as of November 2, 2009 and all new options granted to the holders of those options were fully vested as of the date of grant. The options being granted to any employee of the Company whose employment with the Company will terminate in connection with the closing of the impending sale of the Company's Law Enforcement Division and who will become an employee of the buyer upon such closing shall be exercisable for up to eighteen (18) months from and after the date of grant. The remaining options shall be exercisable for up to three (3) years from and after the date of grant.

The Company has evaluated all subsequent events through November 13, 2009 for potential disclosure in the financial statements.

Table of Contents

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITIONS AND RESULTS OF OPERATIONS

CAUTIONARY STATEMENT FOR FORWARD-LOOKING STATEMENTS

Edgar Filing: BIO KEY INTERNATIONAL INC - Form 10-Q

The information contained in this Report on Form 10-Q and in other public statements by the Company and Company officers include or may contain certain forward-looking statements. All statements other than statements of historical facts contained in this Report on Form 10-Q, including statements regarding our future financial position, business strategy and plans and objectives of management for future operations, are forward-looking statements. The words anticipate, believe, estimate, will, may, future, plan, intend and expect and similar expressions identify forward-looking statements. Although we believe that our plans, intentions and expectations reflected in the forward-looking statements are reasonable, we cannot be sure that they will be achieved. Actual results may differ materially from the forward-looking statements contained herein due to a number of factors.

Many of these factors are set forth in the Company's Annual Report on Form 10-K under the caption Risk Factors and other filings with the Securities and Exchange Commission. These factors are not intended to represent a complete list of the general or specific factors that may affect us. It should be recognized that other factors, including general economic factors and business strategies may be significant, presently or in the future. Except as required by law, we undertake no obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

OVERVIEW

Edgar Filing: BIO KEY INTERNATIONAL INC - Form 10-Q

BIO-key develops and delivers advanced identification solutions and information services to customers in both the private sector and government, including law enforcement departments, and public safety agencies. Our high-performance, yet easy-to-deploy biometric finger identification technology accurately identifies and authenticates users of wireless and enterprise data, improving security, convenience and privacy while reducing identity theft. Our mobile wireless technology provides first responders with critical, reliable, real-time data and images from local, state and national databases. Today, over 750 police departments in North America depend on BIO-key solutions, making us one of the leading supplier of mobile and wireless solutions for public safety worldwide

In 2004, BIO-key acquired Public Safety Group, Inc. (PSG), a privately held company that is a leader in wireless solutions for law enforcement and public safety markets. PSG's primary technology is PocketCop, a handheld solution that provides mobile officers, such as detectives who are not typically in their vehicles, a hand-held mobile information software solution.

Also in 2004, BIO-key completed a transaction with Aether Systems, Inc. to purchase its Mobile Government Division (Mobile Government or AMG), a leading provider of wireless data solutions for use by public safety organizations, primarily state, local police, fire and rescue and emergency medical services organizations. Our PacketCluster mobile information software is integrated with 50 separate State/NCIC databases, as well as other state, local and federal databases. Its open architecture and its published Application Programming Interface (API) make it easy to interface with a wide range of information sources. PacketCluster products deliver real-time information in seconds, freeing dispatchers to handle more pressing emergencies.

In 2007, BIO-key completed a transaction with ZOLL Data Systems, Inc. (ZOLL), a subsidiary of ZOLL Medical Corporation, in which ZOLL acquired substantially all of the assets related to the Company's Fire/EMS Services division.

On August 13, 2009, the Company and InterAct911 Mobile Systems, Inc. (Buyer), a wholly-owned subsidiary of InterAct911 Corporation (the Parent), entered into an Asset Purchase Agreement (the Purchase Agreement), pursuant to which Buyer agreed to purchase the Company's Law Enforcement division (the Business). The Purchase Agreement provides for Buyer to acquire substantially all of the

Table of Contents

assets relating to the Business, including the Company's customer contracts, intellectual property, accounts receivables, equipment, inventories, software, technologies, communication systems and goodwill relating to the Business, and to assume certain specified liabilities as set forth in the Purchase Agreement.

As a result of these transactions, the Company is now one discrete operating segment. Biometric's high performance, scalable, cost-effective and easy-to-deploy biometric fingerprint identification technology identifies and authenticates individuals to improve security, convenience and privacy and to reduce identity theft. The Company continues to focus on its primary objectives of increasing revenue and managing expenses, by continuing to develop and deploy leadership technology and applications, while providing existing and new customers with high quality support and service.

CRITICAL ACCOUNTING POLICIES

For detailed information on our critical accounting policies and estimates, see our financial statements and notes thereto included in this Report and in our Annual Report on Form 10-K, for the year ended December 31, 2008. There have been no material changes to our critical accounting policies and estimates from those disclosed in our 10-K filed on March 11, 2009.

RECENT ACCOUNTING PRONOUNCEMENTS

In June 2009, the FASB issued SFAS No. 168 *The FASB Accounting Standards Codification and the Hierarchy of Generally Accepted Accounting Principles - A Replacement of FASB Statement No. 162* (SFAS 168). SFAS 168 establishes the FASB Accounting Standards Codification™ (Codification) as the single source of authoritative U.S. generally accepted accounting principles (U.S. GAAP) recognized by the FASB to be applied by nongovernmental entities. Rules and interpretive releases of the SEC under authority of federal securities laws are also sources of authoritative U.S. GAAP for SEC registrants. SFAS 168 and the Codification are effective for financial statements issued for interim and annual periods ending after September 15, 2009. When effective, the Codification will supersede all existing non-SEC accounting and reporting standards. All other non-grandfathered, non-SEC accounting literature not included in the Codification will become non-authoritative. Following SFAS 168, the FASB will not issue new standards in the form of Statements, FASB Staff Positions, or Emerging Issues Task Force Abstracts. Instead, the FASB will issue Accounting Standards Updates, which will serve only to: (a) update the Codification; (b) provide background information about the guidance; and (c) provide the bases for conclusions on the change(s) in the Codification. The adoption of SFAS 168 did not have an impact on our consolidated financial statements.

In May 2009, the FASB issued SFAS No. 165, *Subsequent Events* (SFAS 165), which is now part of ASC 855, *Subsequent Events*. SFAS 165 sets forth the period after the balance sheet date during which management of a reporting entity should evaluate events or transactions that may occur for potential recognition or disclosure in the financial statements, the circumstances under which an entity should recognize events or transactions occurring after the balance sheet date in its financial statements, and the disclosures that an entity should make about events or transactions that occurred after the balance sheet date. SFAS 165 will be effective for interim or annual period ending after June 15, 2009 and will be applied prospectively. The Company has adopted the requirements of this pronouncement for this quarter ended June 30, 2009 and will evaluate subsequent events through the day of filing each financial statement.

Edgar Filing: BIO KEY INTERNATIONAL INC - Form 10-Q

In April 2009, the FASB issued FSP No. FAS 115-2 and FAS 124-2, *Recognition and Presentation of Other-Than-Temporary Impairments* (FSP 115-2). Under the new guidance, which is now part of the Accounting Standards Codification (ASC) 320, *Investments - Debt and Equity Securities*, an other than-temporary impairment is recognized when an entity has the intent to sell a debt security or when it is more likely than not that an entity will be required to sell the debt security before its anticipated recovery in value. Additionally, the new guidance changes the presentation and amount of other-than-temporary impairment losses recognized in the income statement for instances in which the Company does

Table of Contents

not intend to sell a debt security, or it is more likely than not that the Company will not be required to sell a debt security prior to the anticipated recovery of its remaining cost basis. The Company separates the credit loss component of the impairment from the amount related to all other factors and reports the credit loss component in net realized investment gains (losses). The impairment related to all other factors if reported in accumulated other changes in equity from nonowner sources. In addition to the changes in measurement and presentation, the disclosures are required to be included in both interim and annual periods. The provisions of the new guidance were effective for interim periods ending after June 15, 2009. The adoption of the new guidance did not have a material effect on the Company's results of operations, financial position or liquidity and we will comply with the guidance going forward.

In April 2009, the FASB issued FSP No. FAS 107-1 and APB 28-1, *Interim Disclosures about Fair Value of Financial Instruments*, which is now part of ASC 825. This FSP essentially expands the disclosure about fair value of financial instruments that were previously required only annually to also be required for interim period reporting. In addition, the FSP requires certain additional disclosures regarding the methods and significant assumptions used to estimate the fair value of financial instruments. These additional disclosures were required beginning with the quarter ended June 30, 2009. The Company has adopted the requirements of this pronouncement effective the quarter ended June 30, 2009.

In February 2009, the Financial Accounting Standards Board (FASB) issued Statement of Financial Accounting Standards (SFAS) No. 141(R)-a, *Accounting for Assets Acquired and Liabilities Assumed in a Business Combination that Arise from Contingencies* (SFAS No. 141(R)-a), now part of ASC 805, which simplifies how entities will be required to account for contingencies arising in business combinations under SFAS 141(R) *Accounting for Business Combinations*. FASB decided to amend the guidance SFAS 141(R) to require assets acquired and liabilities assumed in a business combination that arise from contingencies be recognized at fair value, if fair value can be reasonably estimated. If fair value of such an asset or liability cannot be reasonably estimated, the asset or liability would be accounted for in accordance with FASB Statement No. 5 *Accounting for Contingencies* (SFAS 5). The provisions of SFAS No. 141(R)-a are applicable to business combinations consummated after January 1, 2009 for calendar year entities. The adoption of SFAS 141(R)-a will have an impact on the Company's accounting for business combinations in connection with any future acquisitions.

In December 2007, the FASB issued SFAS No. 160, *Non-controlling Interests in Consolidated Financial Statements - an amendment of ARB No. 51* (SFAS No. 160), which establishes accounting and reporting standards for the non-controlling interest in a subsidiary for the deconsolidation of a subsidiary. Under the guidance, which is now part of the (ASC) 810, *Consolidation*, SFAS No. 160 is effective for financial statements issued for fiscal years beginning after December 15, 2008, and interim statements within those fiscal years. The Company does not currently have any non-controlling interests.

In March 2008, the FASB issued SFAS No. 161, *Disclosures about Derivative Instruments and Hedging Activities*. (SFAS No.161) which amends and expands the disclosure requirements related to derivative instruments and hedging activities. Under the guidance, which is now part of the (ASC) 815, *Derivatives and Hedging Activities*, the Statement requires qualitative disclosures about objectives and strategies for using derivatives, quantitative disclosures about fair value amounts of and gains and losses on derivative instruments, and disclosures about credit-risk-related contingent features in derivative agreements. The provisions of SFAS 161 are effective for the fiscal year beginning January 1, 2009. The Company will comply with the disclosure requirements of this statement since it utilizes derivative instruments.

In October 2008, the FASB issued Staff Position No. FAS 157-3, *Determining the Fair Value of a Financial Asset When the Market for That Asset is Not Active* (FSP 157-3). Under the guidance, which is now part of the Accounting Standards Codification (ASC) 350, *Intangibles Goodwill and Other* (ASC 350), FSP 157-3 clarifies the application of SFAS 157, which the Company adopted as of January 1, 2008, in cases where a market is not active. The Company will comply with the clarification to the original application.

Table of Contents

In November 2008, the FASB ratified the EITF consensus on Issue No. 08-7, *Accounting for Defensive Intangible Assets* (EITF 08-7). Under the guidance, which is now part of the (ASC) 350, *Intangibles - Goodwill and Other*, the consensus addresses the accounting for an intangible asset acquired in a business combination or asset acquisition that an entity does not intend to use or intends to hold to prevent others from obtaining access (a defensive intangible asset). Under EITF 08-7, a defensive intangible asset needs to be accounted as a separate unit of accounting and would be assigned a useful life based on the period over which the asset diminishes in value. EITF 08-7 was effective for transactions occurring after December 31, 2008. The Company will consider this standard in terms of intangible assets in connection with any future acquisitions.

In June 2009, the FASB issued SFAS No. 166 *Accounting for Transfers of Financial Assets* (SFAS 166). Statement 166 is a revision to FASB Statement No. 140, *Accounting for Transfers and Servicing of Financial Assets and Extinguishments of Liabilities* , and will require more information about transfers of financial assets, including securitization transactions, and where entities have continuing exposure to the risks related to transferred financial assets. It eliminates the concept of a qualifying special-purpose entity, changes the requirements for derecognizing financial assets, and requires additional disclosures. SFAS 166 enhances information reported to users of financial statements by providing greater transparency about transfers of financial assets and an entity's continuing involvement in transferred financial assets. SFAS 166 will be effective at the start of a reporting entity's first fiscal year beginning after November 15, 2009. Early application is not permitted. We are currently evaluating the impact of adoption of SFAS 166 on the accounting for our convertible notes and related warrant liabilities. The Company does not expect that the provisions of the new guidance will have a material effect on its results of operations, financial position or liquidity.

In June 2009, the FASB issued SFAS No. 167 *Amendments to FASB Interpretation No. 46(R)* (SFAS 167). Statement 167 is a revision to FASB Interpretation No. 46 (Revised December 2003), *Consolidation of Variable Interest Entities* , and changes how a reporting entity determines when an entity that is insufficiently capitalized or is not controlled through voting (or similar rights) should be consolidated. The determination of whether a reporting entity is required to consolidate another entity is based on, among other things, the other entity's purpose and design and the reporting entity's ability to direct the activities of the other entity that most significantly impact the other entity's economic performance. SFAS 167 will require a reporting entity to provide additional disclosures about its involvement with variable interest entities and any significant changes in risk exposure due to that involvement. A reporting entity will be required to disclose how its involvement with a variable interest entity affects the reporting entity's financial statements. SFAS 167 will be effective at the start of a reporting entity's first fiscal year beginning after November 15, 2009. Early application is not permitted. We are currently evaluating the impact, if any, of adoption of SFAS 167 on our financial statements.

Table of Contents**RESULTS OF OPERATIONS****THREE MONTHS ENDED SEPTEMBER 30, 2009****AS COMPARED TO SEPTEMBER 30, 2008****INTRODUCTION**

Our business now represents the Biometrics segment as the corporate entity, structured to quickly respond to market needs. Our General Manager focuses on growing the business, and driving down costs to achieve profitability.

A detailed analysis can be found below.

Consolidated Results of Operations - Percent Trend

| | Three Months Ended September 30, | |
|--|---|--------------|
| | 2009 | 2008 |
| Revenues | | |
| License fees and other | 83% | 87% |
| Services | 17% | 13% |
| | 100% | 100% |
| Costs and other expenses | | |
| Cost of license fees and other | 34% | 18% |
| Cost of services | 3% | 4% |
| | 37% | 22% |
| Gross Profit | 63% | 78% |
| Operating expenses | | |
| Selling, general and administrative | 143% | 190% |
| Research, development and engineering | 47% | 53% |
| | 190% | 243% |
| Operating Loss | -127% | -165% |
| Other income (deductions) | -20% | 42% |
| Loss from continuing operations | -147% | -123% |
| Income from discontinued operations | 134% | 113% |
| Net loss | -13% | -10% |

Table of Contents

| | Three months ended September 30, | | \$ Change | % Change |
|---------------------------|-------------------------------------|------------|-----------|----------|
| | 2009 | 2008 | | |
| <i>Revenues</i> | | | | |
| License & other | 435,872 | 394,807 | 41,065 | 10% |
| Service | 88,479 | 58,121 | 30,358 | 52% |
| <i>Total Revenue</i> | \$ 524,351 | \$ 452,928 | \$ 71,423 | 16% |
| <i>Cost of goods sold</i> | | | | |
| License & other | 179,286 | 80,751 | 98,535 | 122% |
| Service | 15,499 | 17,540 | (2,041) | -12% |
| <i>Total COGS</i> | \$ 194,785 | \$ 98,291 | \$ 96,494 | 98% |

Revenues

License and other revenue for the three months ended September 30, 2009 increased by 10%, attributable directly to an increase in orders received in the Healthcare industry.

For the three months ended September 30, 2009, service revenue increased 52% from the same period in 2008 as the Company added new maintenance customers.

Geographically, North American sales accounted for approximately 98% and 75% of the Company's total sales for the three month periods.

Costs of goods sold

License and other costs increased for the three months ended September 30, 2009 from the same period in 2008 by 122% due to an increase in orders with associated in hardware costs, which are lower margin sales.

For the three months ended September 30, 2009, cost of services remained relatively flat from the same period in 2008.

Selling, general and administrative

| | Three months ended September 30, | | \$ Change | % Change |
|--|-------------------------------------|------|-----------|----------|
| | 2009 | 2008 | | |

Edgar Filing: BIO KEY INTERNATIONAL INC - Form 10-Q

| | | | | |
|--|---------|---------|-----------|------|
| Selling, general and administrative | 749,771 | 863,240 | (113,469) | -13% |
|--|---------|---------|-----------|------|

SG&A expenses decreased by 13% for the three months ended September 30, 2009 from the same period in 2008 due to lower non-cash compensation, property taxes, and travel expenses.

Table of Contents*Research, development and engineering*

| | Three months ended September 30, | | | |
|--|-------------------------------------|------------|-----------|----------|
| | 2009 | 2008 | \$ Change | % Change |
| Research, development and engineering | \$ 245,318 | \$ 238,915 | \$ 6,403 | 3% |

For the three months ended September 30, 2009, research, development and engineering expenses remained relatively flat from the same period in 2008.

Other income and expense

| | Three months ended September 30, | | | |
|--|-------------------------------------|------------|--------------|----------|
| | 2009 | 2008 | \$ Change | % Change |
| Derivative and warrant fair value adjustments | \$ (102,193) | \$ 73,600 | \$ (175,793) | -239% |
| Interest income | 405 | 42 | 363 | 864% |
| Interest expense | | (746) | 746 | -100% |
| Investment income | | 118,631 | (118,631) | -100% |
| Other income/(expense) | (3,774) | (740) | (3,034) | -410% |
| Total | \$ (105,562) | \$ 190,787 | \$ (296,349) | -155% |

For the three months ended September 30, 2009, derivative and warrant fair value adjustments decreased, when compared to the 2008 period, due to changes in the fair market value of embedded derivatives and detachable warrants issued with convertible debt issued in 2004 and 2005, as well as additional derivatives recorded as a result of financings in 2006. The fair value of the derivatives will fluctuate based on our stock price on the valuation date, the debt conversion price, the volatility of our stock price over a period of time, changes in the value of the risk free interest rate and the time to maturity of the outstanding instruments at different points in time.

For the three months ended September 30, 2009, the increase in the interest income was attributable to the restricted cash account. For the quarter ended September 30, 2009, investment income decreased 100% from three months ended September 30, 2008 when an available-for-sale security was sold at its market value and the income was realized.

Table of Contents**NINE MONTHS ENDED SEPTEMBER 30, 2009 AS COMPARED TO SEPTEMBER 30, 2008****Consolidated Results of Operations - Percent Trend**

| | Nine Months Ended September 30, | |
|--|--|-------------|
| | 2009 | 2008 |
| Revenues | | |
| License fees and other | 77% | 93% |
| Services | 23% | 7% |
| | 100% | 100% |
| Costs and other expenses | | |
| Cost of license fees and other | 26% | 7% |
| Cost of services | 4% | 2% |
| | 30% | 9% |
| Gross Profit | 70% | 91% |
| Operating expenses | | |
| Selling, general and administrative | 184% | 130% |
| Research, development and engineering | 54% | 38% |
| | 238% | 168% |
| Operating loss | -168% | -77% |
| Other income(deductions) | -12% | 8% |
| Loss from continuing operations | -180% | -69% |
| Income from discontinued operations | 202% | 30% |
| Net income (loss) | 22% | -39% |

| | Nine months ended | | | | |
|---------------------------|--------------------------|---------------------|---------------------|-----------------|--|
| | September 30, | | | | |
| | 2009 | 2008 | \$ Change | % Change | |
| <i>Revenues</i> | | | | | |
| License & other | 1,039,247 | 1,889,156 | (849,909) | -45% | |
| Service | 303,983 | 137,667 | 166,316 | 121% | |
| Total Revenue | \$ 1,343,230 | \$ 2,026,823 | \$ (683,593) | -34% | |
| <i>Cost of goods sold</i> | | | | | |
| License & other | 352,088 | 148,472 | 203,616 | 137% | |
| Service | 48,208 | 36,911 | 11,297 | 31% | |
| Total COGS | \$ 400,296 | \$ 185,383 | \$ 214,913 | 116% | |

Revenues

2008 license & other revenues of \$1.9 million included \$900,000 of a single large order for licenses for a significant contract. Without this one time effect, biometric revenues from ongoing business grew 22% year over year for the nine month periods.

Edgar Filing: BIO KEY INTERNATIONAL INC - Form 10-Q

The 121% growth in the 2009 services revenue reflects the impact of the maintenance revenue of the license revenue from that large license order referenced above and from other new customers.

Geographically, North American sales accounted for approximately 98% and 87% of the Company's total sales for the nine month periods ended September 30, 2009 and 2008 respectively.

Table of Contents*Costs of goods sold*

License and other costs increased for the nine months ended September 30, 2009 from the same period in 2008 by 137% due to an increase in costs for temporary outside services required to support specific customer orders, hardware costs for an increase in hardware orders, and third party software.

For the nine months ended September 30, 2009, cost of services increased approximately 31% from the same period in 2008 due to increased customer support, as needed, for the expanding customer base.

Selling, general and administrative

| | Nine months ended September 30, | | | |
|--|------------------------------------|--------------|--------------|----------|
| | 2009 | 2008 | \$ Change | % Change |
| Selling, general and administrative | \$ 2,474,986 | \$ 2,639,630 | \$ (164,644) | -6% |

SG&A costs for the nine months ended September 30, 2009 decreased 6 % compared to the same period in 2008 due to decrease in non-cash compensation charges and travel expenses, offset by increased legal fees related to the Settlement Agreement, and commission expenses.

Research, development and engineering

| | Nine months ended September 30, | | | |
|--|------------------------------------|------------|-------------|----------|
| | 2009 | 2008 | \$ Change | % Change |
| Research, development and engineering | \$ 719,095 | \$ 769,147 | \$ (50,052) | -7% |

For the nine months ended September 30, 2009, research, development and engineering costs decreased 7% from the nine months ended September 30, 2008 due to reductions in temporary outside services.

Table of Contents*Other income and expense*

| | Nine months ended September 30, | | | |
|--|------------------------------------|------------|--------------|----------|
| | 2009 | 2008 | \$ Change | % Change |
| Derivative and warrant fair value adjustments | \$ (157,170) | \$ 62,426 | \$ (219,596) | -352% |
| Interest income | 405 | 1,339 | (934) | -70% |
| Interest expense | | (3,419) | 3,419 | -100% |
| Investment income | | 118,631 | (118,631) | -100% |
| Other expense | (7,148) | (16,882) | 9,734 | -58% |
| Total | \$ (163,913) | \$ 162,095 | \$ (326,008) | -201% |

For the nine months ended September 30, 2009, derivative and warrant fair value adjustments decreased, when compared to the 2008 period, due to changes in the fair market value of embedded derivatives and detachable warrants issued with convertible debt issued in 2004 and 2005, as well as additional derivatives recorded as a result of financings in 2006. The fair value of the derivatives will fluctuate based on our stock price on the valuation date, the debt conversion price, the volatility of our stock price over a period of time, changes in the value of the risk free interest rate and the time to maturity of the outstanding instruments at different points in time.

For the nine months ended September 30, 2009, the increase in the interest income was attributable to the restricted cash account. For the nine months ended September 30, 2009, investment income decreased 100% from three months ended September 30, 2008 when an available-for-sale security was sold at its market value and the income was realized.

LIQUIDITY AND CAPITAL RESOURCES

For the nine months ended September 30, 2009, net cash used in operations was approximately \$638,000, approximately \$2,359,000 used for continuing operations and \$1,720,000 provided by discontinued operations. The cash used for continuing operations was primarily due to the following items:

- Negative cash flow due to a increase in accounts receivable of approximately \$112,000,
- Cash flows of approximately \$164,000 from increase in accounts payable and an increase accrued liabilities of approximately \$185,000,
- Negative cash flows from a decrease in deferred revenue of approximately \$467,000 due to the timing of

billings.

The following non-cash items reflected in the Company's statement of operations are used to reconcile the net loss to the net cash used in operating activities for continuing operations during the nine months ended September 30, 2009:

- The Company issued notes in 2004, 2005 and 2006 and preferred stock in 2006, all of which contained embedded derivatives, and associated warrants. In 2009, the Company recognized a loss of approximately \$157,000 related to the increase in value of the derivatives and associated warrants. The increase in value is driven mainly by the increase in value of the underlying BIO-key stock.
- The Company recorded approximately \$19,000 of charges in 2009 for the expense of amortizing intangible assets.

Table of Contents

- The Company recorded approximately \$69,000 of charges in 2009 for the expense of issuing options to employees for services.

Net cash used in investing activities for the nine months ended September 30, 2009 was approximately \$26,000, primarily used in capital expenditures to upgrade computers and new furniture for the Eagan, MN office.

Working capital deficit at September 30, 2009 was approximately \$2,433,000, as compared positive working capital of approximately \$283,000 at December 31, 2008, the deterioration of which was driven mainly by the newly issued notes payable related to the Settlement Agreement for the Preferred Shares.

Since January 7, 1993 (date of inception), our capital needs have been principally met through proceeds from the sale of equity and debt securities.

We do not expect any material capital expenditures during the next twelve months.

We do not currently maintain a line of credit or term loan with any commercial bank or other financial institution.

Liquidity outlook

At September 30, 2009 our total of cash and cash equivalents was \$904,598 as compared to \$1,712,912 at December 31, 2008.

For approximately the past 18 months the Company has financed itself with internal funds generated from operations and discontinued operations. Previously, the Company had financed itself through access to the capital markets by issuing debt securities, convertible preferred stock and common stock. We currently require approximately \$300,000 per month, to conduct our operations. During the first nine months of 2009, we generated approximately \$1,343,000 of continuing revenue and had a net operating loss for the nine months ended September 30, 2009. While the Company expects to reach profitability by the end of 2009, there can be no assurance that we will.

The Company's Series A Convertible Preferred Stock was redeemable in cash by the stockholders within 10 days after December 31, 2008, since certain stock price performance conditions were not met. This obligation is still outstanding and continues to accrue dividends at an increased default rate.

Edgar Filing: BIO KEY INTERNATIONAL INC - Form 10-Q

In addition, the Company's Series B and Series C Convertible Preferred Stock were redeemable in cash by the stockholders during the first quarter of 2009, since certain stock price performance conditions were not met. These obligations are still outstanding and continue to accrue dividends at an increased default rate. The Company expects to use some of the proceeds from the sale of Law Enforcement Division to redeem the Preferred Stock.

The Company has received waivers from the holders of 64% of the outstanding preferred shares, representing 89% of the outstanding shares other than the shares held by Longview Special Finance, Inc. and Longview Fund, L.P. The Company has entered into a Settlement Agreement with Longview Special Finance, Inc. and Longview Fund, L.P. whereby we were required to pay a total of \$2,164,922 by October 30, 2009. From October 30, 2009 until November 12, 2009, interest on the remaining portion of the settlement amount accrued at twenty percent (20%) per annum. On November 12, 2009, the Company paid in full the entire outstanding portion of the settlement amount, together with all accrued and unpaid interest, and satisfied all of its obligations to the Longview Entities under the Settlement Agreement. We have taken out an unsecured promissory note (the Note) with the Shaar Fund, Ltd. (Shaar), due and payable on November 4, 2009, to pay half of the obligation on July 7, 2009. Shaar (a) has extended the due date of the Note to the earlier to occur of (i) the fifth business day after the closing of the Asset Sale (as defined below)

Table of Contents

and (ii) January 31, 2010 pursuant to a Note Amendment and Extension Agreement dated as of November 3, 2009 between the Company and Shaar, and (b) has made a bridge loan to the Company in the principal amount of \$750,000, evidenced by the Company's unsecured Six Percent (6%) Promissory Note dated as of November 12, 2009. The bridge note of \$750,000 plus interest is due on the earlier of 5 days after the sale of the Law Enforcement Division or January 31, 2010.

In consideration thereof, Shaar and the Company also entered into a Securities Exchange Agreement dated as of November 12, 2009 (the Exchange Agreement), pursuant to which the Company and the holders of the outstanding shares of the Company's Series A Convertible Preferred Stock, \$0.0001 par value per share (the Series A Preferred Stock), such holders being Shaar (27,932 shares) and Thomas J. Colatosti (2,625 shares), agreed to exchange (a) their shares of Series A Preferred Stock for an equal number of shares of the Company's Series D Convertible Preferred Stock, \$0.0001 par value per share (the Series D Preferred Stock), and Warrants to purchase up to an aggregate of 5,000,000 shares of the Company's Common Stock, including up to 4,750,000 shares to Shaar and up to 250,000 shares to Mr. Colatosti, at an exercise price of \$0.30 per share, and (b) all dividends accrued and unpaid on their shares of Series A Preferred Stock for Seven Percent (7%) Convertible Promissory Notes (the Convertible Notes). The Series D Preferred Stock is mandatorily redeemable on December 31, 2010, at which time the Company is to redeem for cash all outstanding shares at \$100 per share, together with all accrued and unpaid dividends thereon. The Convertible Notes may be converted in whole or in part at any time at the option of the holder into shares of the Company's Common Stock at a price equal to the lower of (i) the average closing price of the Common Stock as quoted by Bloomberg for the ten (10) trading days prior to the date that the notice of conversion is transmitted to the Company, and (ii) \$0.30, subject to certain adjustments. The closing of the transactions contemplated by the Exchange Agreement is conditioned upon, among other things, the closing of the Asset Sale.

If we are unable to generate sufficient revenue to meet our goals, we will need to obtain additional third-party financing to (i) conduct the sales, marketing and technical support necessary to execute our plan to substantially grow operations, increase revenue and serve a significant customer base; and (ii) provide working capital. Therefore, we will need to obtain additional financing through the issuance of debt or equity securities, or to restructure our financial position through similar transactions to those consummated during 2006 and 2007.

Due to several factors, including our history of losses and limited revenue, our former and current independent auditors have included an explanatory paragraph in opinions they have previously issued related to our annual financial statements as to the substantial doubt about our ability to continue as a going concern. Our long-term viability and growth will depend upon the successful commercialization of our technologies and our ability to obtain adequate financing. In addition, the recent financial crisis in the global capital markets and the current negative global economic trends have had an adverse impact on market participants including, among other things, volatility in security prices, diminished liquidity, and limited access to financing. These events could, therefore, affect our efforts to commercialize our technology and to obtain adequate financing. In particular, these conditions could impact the ability and willingness of our current and prospective customers to make investments in our technology and pay their obligations to us. To the extent that we require such additional financing, no assurance can be given that any form of additional financing will be available on terms acceptable to us, that adequate financing will be obtained to meet our needs, or that such financing would not be dilutive to existing stockholders. If available financing is insufficient or we fail to continue to generate meaningful revenue, we may be required to further reduce operating expenses, delay the expansion of operations, be unable to pursue merger or acquisition candidates, or continue as a going concern.

Table of Contents

ITEM 4. CONTROLS AND PROCEDURES

Edgar Filing: BIO KEY INTERNATIONAL INC - Form 10-Q

Evaluation of Disclosure Controls and Procedures

An evaluation of the effectiveness of the Company's disclosure controls and procedures (as such term is defined in Rules 13(a)-15(e) of the Securities Exchange Act of 1934, as amended (the Exchange Act)) as of September 30, 2009 was carried out by the Company under the supervision and with the participation of the Company's Chief Executive Officer (CEO) and Chief Financial Officer (CFO).

During the review of the Company's operating results for the period covered by this report, our CEO and CFO determined that, as of September 30, 2009, our disclosure controls and procedures were effective in providing reasonable assurance that information we are required to disclose in reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified by the Securities and Exchange Commission rules and forms. Our management reached this conclusion after identifying our system to capture disclosure items, our internal process of review for account reconciliations, our documentation of internal controls and our internal process for preparing our quarterly report on Form 10-Q for the quarterly period ended September 30, 2009 as being adequate to provide such assurance.

Changes in Internal Control Over Financial Reporting.

There have been no changes in our internal control over financial reporting occurred during the fiscal quarter ended September 30, 2009 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

Effective as of July 2, 2009, the Company entered into a Settlement and Mutual Release Agreement (the Settlement Agreement) with Longview Special Finance, Inc. and Longview Fund, L.P. (collectively, the Longview Entities) in order to resolve all matters relating to the litigation initiated by the Longview Entities earlier this year, in which they were seeking \$2,886,563 in damages and an unspecified amount of interest and attorney's fees from the Company as a result of the Company's alleged improper failure to redeem their outstanding shares of the Company's Convertible Preferred Stock (collectively, the Shares) in accordance with the terms and conditions of such preferred stock. Pursuant to the Settlement Agreement, without admission of any liability or fault, the parties agreed to a payment schedule under which the Company is required to pay a total cash settlement amount of \$2,164,922, fifty percent (50%) of which was paid on July 7, 2009. The remaining portion of the settlement amount will bear interest at seventeen percent (17%) per annum and was required to be paid in full on or before October 30, 2009. In return, the Longview Entities agreed to a full and complete release of the Company from all claims that were or could have been alleged in the lawsuit and agreed to relinquish all of the Shares upon receiving final payment of the settlement amount. From October 30, 2009 until November 12, 2009, interest on the remaining portion of the settlement amount accrued at twenty percent (20%) per annum. On November 12, 2009, the Company paid in full the entire outstanding portion of the settlement amount, together with all accrued and unpaid interest, and satisfied all of its obligations to the Longview Entities under the Settlement Agreement.

ITEM 6. EXHIBITS

The exhibits listed in the Exhibits Index immediately preceding such exhibits are filed as part of this Report.

Table of Contents

SIGNATURES

Edgar Filing: BIO KEY INTERNATIONAL INC - Form 10-Q

In accordance with the requirements of the Securities Exchange Act of 1934, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

BIO-Key International, Inc.

Dated: November 13, 2009

/s/ Michael W. DePasquale
Michael W. DePasquale
Chief Executive Officer

Dated: November 13, 2009

/s/ THOMAS J. COLATOSTI
Thomas J. Colatosti
Chief Financial Officer

Table of Contents

EXHIBIT INDEX

| Exhibit No. | Description |
|--------------------|--|
| 10.1 (1) | Settlement and Mutual Release Agreement, dated July 2, 2009, by and between the Company and Longview Special Finance, Inc. and Longview Fund, L.P. |
| 10.2 (1) | Promissory Note, dated July 7, 2009, issued by the Company to the Shaar Fund, Ltd. |
| 31.1(1) | Certificate of CEO of Registrant required under Rule 13a-15(f) under the Securities Exchange Act of 1934, as amended |
| 31.2 (1) | Certificate of CFO of Registrant required under Rule 13a-15(f) under the Securities Exchange Act of 1934, as amended |
| 32.1(1) | Certificate of CEO of Registrant required under 18 U.S.C. Section 1350 |
| 32.2 (1) | Certificate of CFO of Registrant required under 18 U.S.C. Section 1350 |

(1) Filed herewith